PHR: GENETICS, GENOMICS AND EPIGENETICS RESEARCH PROGRAM – NARRATIVE Not applicable.

PI_NAMEs: PUSZTAI, LAJOS  (contact)

PROJECT_TERMS: Academy;Address;Algorithmic Software;Algorithms;analytical tool;anti-cancer research;Antibody-drug conjugates;Award;Binding;biobank;blockchain;Cancer Burden;Cancer Center Support Grant;cancer genetics;cancer genome;cancer genomics;cancer initiation;Cancer Model;CAR T cell therapy;career;Catchment Area;Clinical;clinical trial analysis;Clinical Trials;Code;Collaborations;Communities;Computational algorithm;CRISPR screen;Data;Data Analyses;data resource;data sharing;Dedications;Development;Developmental Therapeutics Program;Diagnostic tests;Direct Costs;Drug resistance;early onset;environmental mutagens;Epigenetic Process;epigenome;epigenomics;Faculty;Feedback;Fostering;Funding;Funding Mechanisms;Future;Genetic;Genetic Transcription;Genome;genome-wide;genomic data;genomic tools;Genomics;Germ Lines;Goals;graduate student;health care disparity;Human Genome;Immune Evasion;Immunotherapy;innovation;Interdisciplinary Study;interest;Interest Group;International;investigator-initiated trial;Journals;Knowledge;Laboratories;Lead;Leadership;Malignant - descriptor;Malignant Breast Neoplasm;Malignant neoplasm of liver;Malignant neoplasm of lung;Malignant neoplasm of prostate;Malignant Neoplasms;medical schools;Medicine;member;Mentorship;Metabolic;Metabolism;Modeling;mouse model;multidimensional data;Mutation;Neoplasm Metastasis;new technology;next generation;novel;novel diagnostics;novel therapeutic intervention;novel therapeutics;Obesity;Paper;Pathology;Patients;Peer Review;Phenotype;Positioning Attribute;Postdoctoral Fellow;pre-clinical;predictive marker;prognostic assays;programs;prospective;Publications;Publishing;randomized, clinical trials;recruit;Research;Research Personnel;Resource Development;Resources;Role;Science;Scientist;Secure;single cell sequencing;Site Visit;Smoking;Software Tools;Students;symposium;Talents;targeted cancer therapy;technology platform;therapeutic candidate;Therapeutic Research;tissue archive;Tissues;tool;Training;transcriptomics;Translating;United States National Academy of Sciences;Untranslated RNA;Validation;Variant;Vision;Visualization;young adult

PROJECT_TITLE: Genomics, Genetics and Epigenetics Research Program


ADMINISTERING_IC: CA

ARRA_FUNDED: N

FUNDING_MECHANISM: RESEARCH CENTERS

IC_NAME: NATIONAL CANCER INSTITUTE

ORG_CITY: NEW HAVEN

ORG_COUNTRY: UNITED STATES

ORG_FIPS: US

ORG_NAME: YALE UNIVERSITY

ORG_STATE: CT

PHR: RADIOBIOLOGY AND GENOME INTEGRITY RESEARCH PROGRAM – NARRATIVE Not applicable.

PI_NAMEs: KING, MEGAN C (contact)

PROJECT_TERMS: anti-cancer research;Antibodies;Automobile Driving;Award;Back;Basic Science;Biological Markers;BRCA mutations;Breast;Cancer Center Support Grant;cancer imaging;cancer therapy;career;Catchment Area;Cells;Clinic;Clinical;clinical decision-making;clinical translation;Code;Collaborations;Communities;community center;community engagement;Defect;design;Detection;Developmental Therapeutics Program;Direct Costs;Discipline;Disease;DNA Damage;DNA Markers;DNA Repair;DNA Repair Disorder;Education;Educational workshop;Effectiveness;efficacy evaluation;empowerment;Environment;Equity;equity, diversity, and inclusion;Etiology;Experimental Neoplasms;Faculty;Fostering;Funding;Funding Opportunities;Future;genome integrity;Goals;health equity;Home;Image;Image Analysis;imaging approach;imaging modality;imaging science;Immune;improved;Infrastructure;insight;Interdisciplinary Study;Intervention;Investigation;Investments;Journals;Knowledge;Leadership;liquid biopsy;Machine Learning;Magnetic Resonance Imaging;Maintenance;Malignant - descriptor;Malignant Neoplasms;medical schools;meetings;member;Metabolism;Mission;Modeling;Molecular;Molecular Target;neoplastic cell;new technology;new therapeutic target;next generation;novel;novel therapeutic intervention;novel therapeutics;Pancreas;Paper;Participant;Pathway interactions;Peer Review;pharmacologic;Physicians;Positron-Emission Tomography;pre-clinical;Pre-Clinical Model;Predisposition;programs;Prostate;Publishing;radiation delivery;radiation effect;Radiation enhancer;Radiation Oncology;radiation resistance;radiation response;Radiation therapy;Radiobiology;recruit;Research;Research Personnel;Research Priority;Research Support;Resistance;response;Sampling;Science;Scientist;Series;small molecule;Strategic Planning;success;synergism;targeted treatment;Testing;Therapeutic;Therapeutic Research;Tobacco;Tobacco-Related Carcinoma;Training;Training Programs;Translating;Translations;treatment and outcome;tumor;Work;X-Ray Computed Tomography;Yale Cancer Center

PROJECT_TITLE: Radiobiology & Genome Integrity Research Program

STUDY_SECTION: NCI

STUDY_SECTION_NAME: Cancer Centers Study Section (A)[NCI-A]


NIH_SPENDING_CATS: Cancer

PHR: CANCER SIGNALING NETWORKS RESEARCH PROGRAM – NARRATIVE Not applicable.

PI_NAMEs: POLITI, KATERINA ABIGAIL (contact)

PROJECT_TERMS: Acceleration;Address;Affect;Area;Award;Basic Cancer Research;Basic Science;biobank;Biochemical;Biochemical Pathway;Biological Assay;Biological Markers;Biological Models;Breast;Cancer Biology;Cancer Center Support Grant;Cancer Patient;career;Catchment Area;Cell Communication;Clinic;Clinical;clinical application;Clinical Course of Disease;clinical investigation;Clinical Investigator;Clinical Trials;Code;Collaborations;Communities;comorbidity;Developmental Therapeutics Program;Direct Costs;Discipline;Disparity;Drug resistance;Evolution;FDA approved;fundamental research;Funding;Generations;Goals;Grant;improved;improved outcome;Incidence;Knowledge;Lead;Leadership;Liver;Liver Fibrosis;Lung;Malignant - descriptor;Malignant Breast Neoplasm;Malignant neoplasm of liver;Malignant neoplasm of lung;Malignant neoplasm of prostate;Malignant Neoplasms;member;Mentorship;Metabolism;Mission;Neoplasm Metastasis;new technology;new therapeutic target;next generation;novel;novel strategies;Obesity;Paper;Pathway interactions;Patient-Focused Outcomes;Patients;Peer Review;Play;Population;Positioning Attribute;programs;Prostate;Publishing;Regulation;Research;Research Activity;Research Personnel;Research Priority;response;Risk Factors;Science;Signal Transduction;Smoking;smoking-related disease;Specimen;standard of care;Strategic Planning;success;Syndrome;targeted agent;targeted treatment;Technology;Therapeutic;Therapeutic Intervention;Therapeutic Research;therapy resistant;Tobacco use;Training;Translating;translational cancer research;Translational Research;Translations;tumor;tumor metabolism;tumor microenvironment;Tyrosine Kinase Inhibitor;Work

PROJECT_TITLE: Cancer Signaling Networks Research Program


NIH_SPENDING_CATS: Cancer;Health Disparities Research;Health Disparities and Racial or Ethnic Minority Health Research

PHR: DEVELOPMENTAL FUNDS – NARRATIVE Not applicable.

PI_NAMEs: WINER, ERIC P (contact)

PROJECT_TERMS: Advanced Malignant Neoplasm;Affect;anti-cancer research;Applications Grants;Area;Attention;Award;Basic Science;Biological;Cancer Center Support Grant;cancer health disparity;cancer research center director;Cancer Research Project;cancer therapy;career;Catchment Area;Categories;Clinical Research;Clinical Sciences;clinical translation;Clinical Trials;Collaborations;Communication;Communities;community based research;community engagement;Community Outreach;Development;disparity reduction;early onset;Educational workshop;equity, diversity, and inclusion;Evaluation;experience;Faculty;Fostering;Fruit;Funding;Funding Mechanisms;Future;Goals;Grant;health care disparity;health disparity;high reward;high risk;Individual;innovation;Institution;Interdisciplinary Study;Investments;Journals;Laboratories;Leadership;Malignant Breast Neoplasm;Malignant neoplasm of liver;Malignant neoplasm of lung;Malignant neoplasm of prostate;Malignant Neoplasms;Medical;member;Mentors;Metabolism;Metastatic malignant neoplasm to brain;multidisciplinary;NCI Center for Cancer Research;neoplasm resource;Obesity;organizational structure;Outcome;Peer Review;Phase;Play;Population Research;Population Sciences;Prevention;Process;Program Research Project Grants;programs;Publications;Recommendation;Research;Research Personnel;Research Priority;Research Project Grants;Research Proposals;Research Support;Resource Sharing;Role;Science;Scientist;Source;Strategic Planning;Supplementation;Teacher Professional Development;Testing;Thinking;Tobacco;Training;Training and Education;Translational Research;United States National Institutes of Health;Writing;Yale Cancer Center

PROJECT_TITLE: Developmental Funds


PHR: LEADERSHIP, PLANNING AND EVALUATION – NARRATIVE Not applicable.

PROJECT_TERMS: Advisory Committees;anti-cancer research;Area;Basic Science;Cancer Burden;cancer care;Cancer Center Support Grant;cancer health disparity;career development;Caring;Catchment Area;Clinical;clinical care;Clinical Sciences;Clinical Trials;Committee Membership;Communities;Connecticut;Continuity of Patient Care;Disease;disenfranchised population;Doctor of Philosophy;empowerment;Ensure;Equity;equity, diversity, and inclusion;Evaluation;Fostering;Future;Goals;improved;Incubators;Individual;innovation;Leadership;member;Mission;multidisciplinary;Patients;Persons;population based;Population Sciences;Prevention strategy;Recommendation;Research;Resource Sharing;Strategic Planning;success;Training;Training and Education;Translating;Translational Research;treatment strategy;Vision;Work;Yale Cancer Center

PROJECT_TITLE: Leadership, Planning and Evaluation


NIH_SPENDING_CATS: Aging;Cancer;Clinical Research;Health Disparities Research;Health Disparities and Racial or Ethnic Minority Health Research;Health Services;Lung;Lung Cancer;Prevention;Social Determinants of Health

PHR: COMMUNITY OUTREACH AND ENGAGEMENT – NARRATIVE Not applicable.

PI_NAMEs: NUNEZ-SMITH, MARCELLA  (contact)

PROJECT_TERMS: Acceleration;Address;Adult;age group;age related;anti-cancer research;Area;Awareness;Breast;Cancer Burden;cancer care;Cancer Center;Cancer Center Support Grant;cancer clinical trial;Cancer Control;cancer health disparity;Cancer Hospital;Cancer Science;Caring;catalyst;Catchment Area;Clinical Trials;Collaborations;Communication;Communities;community advisory board;community engagement;community organizations;Community Outreach;community partners;community research;Comprehensive Cancer Center;Connecticut;Continuity of Patient Care;Coordination and Collaboration;County;Data;Data Reporting;design;Diagnosis;Drug resistance;Early Diagnosis;early onset;Equity;Evidence based practice;Faculty;health equity;Health Policy;Health system;improved;Incidence;Income;Individual;Inequality;Infrastructure;innovation;Institution;Investments;Knowledge;Leadership;Learning;Liver;Malignant Breast Neoplasm;Malignant neoplasm of liver;Malignant neoplasm of lung;Malignant neoplasm of prostate;Malignant Neoplasms;marginalization;medical schools;member;Metabolism;Metastatic malignant neoplasm to brain;Mission;mortality;NCI Center for Cancer Research;NCI-Designated Cancer Center;Obesity;older adult;Outcome;outreach;Participant;Patients;Pattern;Persons;Population;Prevention;Preventive care;Procedures;programs;Public Health Schools;Puerto Rican;Research;Research Activity;Research Personnel;Research Priority;Research Support;residential segregation;Resources;Risk Factors;Science;Scientist;Shapes;social factors;sociodemographic factors;stakeholder perspectives;Strategic Planning;structural determinants;Tobacco use;tool;Training;Trust;tumor registry;Underserved Population;Urban Population;Vision;Voice;Yale Cancer Center

PROJECT_TITLE: Community Outreach and Engagement


NIH_SPENDING_CATS: Aging;Cancer;Health Disparities Research;Health Disparities and Racial or Ethnic Minority Health Research;Patient Safety;Racial and Ethnic Minority Health Research;Social Determinants of Health

PHR: CLINICAL PROTOCOL AND DATA MANAGEMENT – NARRATIVE Not applicable.

PI_NAMEs: KROP, IAN E (contact)

PROJECT_TERMS: Address;Adult;Advocate;Age;Age disparity;aged;Budgets;Cancer Center Support Grant;cancer clinical trial;Career Ladders;Catchment Area;Child;Clinical Cancer Center;Clinical Data;Clinical Protocols;Clinical Research;Clinical Research Protocols;Clinical Trials;Collection;Communication;community collaboration;community engagement;Community Outreach;Complex;Comprehensive Cancer Center;Conduct Clinical Trials;Contracts;COVID-19 pandemic;Data;data management;Data Reporting;Dedications;Development;disenfranchised population;Enrollment;Ensure;Ethics;ethnic disparity;experience;Faculty;gender disparity;Growth;human old age (65+);improved;Individual;Institution;Intervention;Intervention Studies;investigator-initiated trial;Laboratories;Leadership;life span;Marketing;Measures;Medical;Minority;Monitor;NCI Center for Cancer Research;novel;Occupational activity of managing finances;organizational structure;Outcome Study;patient engagement;patient safety;Patients;Policies;Population Heterogeneity;Positioning Attribute;Procedures;Process;Progress Reports;Protocol Compliance;protocol development;Protocols documentation;Publications;Quality Control;racial disparity;racial minority;recruit;Reporting;repository;Research;Research Personnel;research study;Resources;Review Committee;Risk;Safety;Serious Adverse Event;Services;Site;Specimen Handling;Strategic Planning;Time;Training;Training and Education;treatment trial;trial enrollment;Underrepresented Minority;United States National Institutes of Health;Vision;Wages;Woman;Yale Cancer Center

PROJECT_TITLE: Clinical Protocol and Data Management


PHR: PROTOCOL REVIEW AND MONITORING SYSTEM – NARRATIVE Not applicable.

PI_NAMEs: ZEIDAN, AMER M (contact)

PROJECT_TERMS: Amendment;Appointment;authority;Biometry;Cancer Center Support Grant;cancer research center director;Catchment Area;Clinical Research;Clinical Sciences;Clinical Trials;Committee Membership;Data;Databases;design;Discipline;Disease;Doctor of Philosophy;Enrollment;Ensure;expedited review;Feasibility Studies;Goals;human subject;improved;Individual;Institutional Review Boards;Intervention Studies;Leadership;life span;Malignant Neoplasms;meetings;member;Minority;Mission;Modality;Monitor;Outcome;Outcome Study;patient population;Peer Review;Process;Protocols documentation;Qualifying;Reporting;Research;Research Priority;response;Review Committee;Risk;Risk Assessment;Role;Safety;Scientific Evaluation;Site;sound;Standardization;Strategic Planning;System;Time;Universities;Woman;Writing;Yale Cancer Center

PROJECT_TITLE: Protocol Review and Monitoring System


PHR: BIOSTATISTICS SHARED RESOURCE – NARRATIVE Not applicable.

PI_NAMEs: MA, SHUANGGE  (contact)

PROJECT_TERMS: advanced analytics;anti-cancer research;Area;Basic Science;Bioinformatics;Biometry;Biostatistics Shared Resource;Cancer Center Support Grant;cancer genetics;Clinical Sciences;Clinical Trials;Collaborations;Computer software;Consultations;cost;cost effective;COVID-19;Data Analyses;Data Science;Department chair;Development;Doctor of Philosophy;Educational workshop;Ensure;experience;Faculty;frontier;Funding;Gatekeeping;genetic epidemiology;Goals;Home;Image;Infrastructure;lectures;Malignant Neoplasms;medical schools;Medical Students;Medicine;Methods;Pilot Projects;Play;Population Sciences;Population Study;professor;programs;Protocols documentation;Public Health;Public Health Schools;recruit;Research;Research Design;Research Personnel;Resource Sharing;Resources;Role;Schools;Science;Students;Techniques;Time;Training;Translational Research;Universities;Work;Yale Cancer Center

PROJECT_TITLE: Biostatistics Shared Resource


NIH_SPENDING_CATS: Biotechnology;Cancer;Radiation Oncology

PHR: IRRADIATOR SHARED RESOURCE – NARRATIVE Not applicable.

PI_NAMEs: CHEN, ZHE  (contact)

PROJECT_TERMS: Animal Experimentation;Animals;anti-cancer research;Antitumor Response;Basic Science;Biological;biological effect of radiation;Cancer Center;Cancer Center Support Grant;Capital;Cell Culture Techniques;Cells;Cesium;Chemicals;Collimator;Consultations;Controlled Environment;cost;cost effective;design;DNA;Dose Rate;Ensure;Epigenetic Process;Experimental Designs;experimental study;Funding;Gamma Rays;Genetic;genome integrity;Genomics;Human;image guided;Immune response;Immunosuppression;improved;Individual;Induction of Apoptosis;ionization;Ionizing radiation;irradiation;Lesion;Maintenance;Malignant Neoplasms;member;Molecular;Mus;Mutation;Names;neoplastic cell;Pathway interactions;Physicians;Principal Investigator;programs;quality assurance;Radiation;radiation effect;Radiation induced damage;Radiation Physics;Radiobiology;Recommendation;repaired;Research;Research Personnel;research study;Resource Sharing;Resources;Roentgen Rays;Sampling;Scientist;Services;Signal Transduction;Spleen;Technology;tool;Training;Transgenic Animals;tumor immunology;Universities;Yale Cancer Center

PROJECT_TITLE: Irradiator Shared Resource


PHR: PRECISION CANCER MODELING SHARED RESOURCE – NARRATIVE Not applicable.

PI_NAMEs: MUTHUSAMY, VISH  (contact)

PROJECT_TERMS: 3-Dimensional;Abscopal effect;Agreement;animal imaging;Animal Model;Animal Testing;Animals;Bioluminescence;Calibration;Cancer Center Support Grant;Cancer Model;cancer therapy;Communities;Consultations;Custom;Data;Development;Engineering;Evaluation;Evaluation Studies;Fluorescence;Funding;Generations;Image;imager;imaging study;Immunotherapy;in vivo;in vivo imaging;Industry;Infrastructure;innovation;Institution;Instruction;instrument;interest;Investigational Therapies;Knock-out;Laboratories;Location;Magnetic Resonance Imaging;member;Mission;Modeling;mouse model;Neoplasm Metastasis;novel;novel therapeutics;Pharmacology;pre-clinical;preclinical evaluation;Recommendation;Research;Resistance;Resolution;Resource Sharing;response;Roentgen Rays;Services;standard of care;Surveys;Technology;Therapeutic;therapeutic evaluation;Training;Translating;tumor;Validation;Yale Cancer Center

PROJECT_TITLE: Precision Cancer Modeling Shared Resource


PHR: FLOW CYTOMETRY SHARED RESOURCE – NARRATIVE Not applicable.

PI_NAMEs: HABERMAN, ANN M (contact)

PROJECT_TERMS: anti-cancer research;Antibodies;base;Biological Assay;Biological Response Modifier Therapy;cancer cell;Cancer Center Support Grant;Cell Separation;Cells;Clinical;Clinical Trials;Clustered Regularly Interspaced Short Palindromic Repeats;Collaborations;Collection;community center;Complex;Computer software;Consultations;Correlative Study;cost;Cryopreservation;Custom;Data;data acquisition;Data Analyses;design;Development;Emerging Technologies;empowerment;Ensure;Epigenetic Process;Equipment;Event;experience;extracellular;Fee-for-Service Plans;Flow Cytometry;Flow Cytometry Shared Resource;Fluorescence;fluorophore;Funding;Genes;Genetic;Genomics;Heterogeneity;Image;Immune;indexing;Individual;innovation;Institution;instrument;Laboratories;Licensing;Malignant Neoplasms;Medical Research;medical schools;member;metabolomics;operation;Peptides;Performance;Peripheral Blood Mononuclear Cell;Phenotype;Plasma;Population;Pre-Clinical Model;Preparation;programs;Proteins;Proteomics;Protocols documentation;Recovery;Research;Research Design;Research Personnel;Resource Sharing;Resources;Retrieval;Sampling;Services;Signal Pathway;Signal Transduction;Site;Sorting;Stains;System;Techniques;Technology;tool;Training;transcriptome sequencing;transcriptomics;Treatment Efficacy;tumor immunology;tumor microenvironment;Tumor Stem Cells;tumorigenesis;Yale Cancer Center

PROJECT_TITLE: Flow Cytometry Shared Resource


PHR: RAPID CASE ASCERTAINMENT SHARED RESOURCE – NARRATIVE Not applicable.

PI_NAMEs: MEHTA, RAJNI  (contact)

PROJECT_TERMS: abstracting;Address;Aftercare;Annual Reports;anti-cancer research;Area;Biological Assay;Biopsy;Blood;Cancer Center Support Grant;cancer diagnosis;cancer epidemiology;Catchment Area;Categories;Cerebrospinal Fluid;Cities;Clinical;Clinical Research;cohort;Collection;Connecticut;Consent;Consultations;Core Biopsy;cost effective;Data;Data Collection;epidemiology study;falls;Feasibility Studies;Feces;Goals;Health Insurance Portability and Accountability Act;High-Risk Cancer;Histologic;Histology;Hospitals;human subject protection;Individual;Institution;Institutional Review Boards;Interview;Malignant Neoplasms;Medical Records;member;Newly Diagnosed;Paper;participant enrollment;Pathology;Patients;population based;Population Study;programs;prospective;Protocols documentation;Public Health;Regulation;Research;Research Design;Research Personnel;Research Project Grants;research study;Resource Sharing;Resources;response;Retrieval;sample collection;Services;Site;Slide;Specimen;Standardization;success;Tissues;tumor;tumor registry;Veterans Health Administration;Writing

PROJECT_TITLE: Rapid Case Ascertainment Shared Resource


PHR: YALE CENTER FOR GENOME ANALYSIS SHARED RESOURCE – NARRATIVE Not applicable.

PI_NAMEs: MANE, SHRIKANT M (contact)

PROJECT_TERMS: Applications Grants;Bioinformatics;Biological Assay;Biological Sciences;Biotechnology;Cancer Biology;Cancer Center Support Grant;Cells;Computer software;Consultations;cost;Custom;Data Analyses;data quality;Dedications;design;Development;DNA;DNA sequencing;Doctor of Philosophy;Educational workshop;Ensure;Epigenetic Process;Equipment;experience;Experimental Designs;experimental study;Funding;Genetic;genome analysis;Genomics;Genotype;Grant;High Performance Computing;improved;In Situ Hybridization;interest;Laboratories;Large-Scale Sequencing;Libraries;Linux;Malignant Neoplasms;member;Methodology;Methods;Methylation;Mission;multiple omics;nano-string;nanopore;new technology;next generation sequencing;Preparation;Principal Investigator;professor;programs;Proteins;Protocols documentation;Research;research and development;Research Personnel;Resource Sharing;Resources;RNA;RNA analysis;Sampling;Scientist;secondary analysis;sequencing platform;service utilization;Services;single cell genomics;single cell sequencing;square foot;Technology;Testing;tool;Training;Training and Education;transcriptome sequencing;transcriptomics;tumor immunology;United States National Institutes of Health;Variant;Vendor;Wages;Work;Writing;Yale Cancer Center

PROJECT_TITLE: Yale Center for Genome Analysis Shared Resource


PHR: YALE CENTER FOR MOLECULAR DISCOVERY SHARED RESOURCE – NARRATIVE Not applicable.

PI_NAMEs: CREWS, CRAIG M (contact)

PROJECT_TERMS: Academia;Acceleration;Acoustics;Address;Area;assay development;base;Basic Science;Biochemical;Biological;Biological Assay;Biological Process;Cancer Center Support Grant;Cells;Cellular Assay;Chemicals;Clinical;Collection;Communities;Computer software;Core Facility;cost effective;cost effectiveness;CRISPR screen;Data Analyses;Databases;design;Development;Devices;Drops;drug discovery;Ensure;Epigenetic Process;experience;experimental study;Faculty;Genes;Genetic;Genetic Screening;genome-wide;Genomic Library;Genomics;Goals;Guide RNA;high throughput screening;Human Genome;Industry;Infrastructure;innovation;insight;instrument;instrumentation;Kinetics;Knowledge;Laboratories;Libraries;Liquid substance;member;Microscopy;miniaturize;Mining;Mission;model organism;Molecular;NCI Center for Cancer Research;new therapeutic target;novel;novel therapeutics;Outcome;Outsourcing;Pathway interactions;Pharmaceutical Preparations;Pharmacologic Substance;Productivity;programs;Reader;Reagent;Registries;Research;Research Contracts;Research Methodology;Research Personnel;Resource Sharing;Resources;Robot;Robotics;Scientist;screening;Services;Side;Small Interfering RNA;small molecule;success;synergism;synthetic drug;System;Technology;Testing;Therapeutic;Time;tool;Training;Translational Research;translational research program;Validation;Work;Yale Cancer Center

PROJECT_TITLE: Yale Center for Molecular Discovery Shared Resource


PHR: YALE PATHOLOGY TISSUE SERVICES SHARED RESOURCE – NARRATIVE Not applicable.

PI_NAMEs: RIMM, DAVID L (contact)

PROJECT_TERMS: Accounting;Anatomy;animal tissue;Animals;Archives;biobank;Cancer Center Support Grant;Certification;Clinical Trials;cohort;Computer software;Data;Databases;Dedications;Development;Diagnostic;digital;Disease;Doctor of Philosophy;Drug or chemical Tissue Distribution;Freezing;Frozen Sections;Future;Head and Neck Squamous Cell Carcinoma;Histology;Human;human tissue;Image Analysis;Immunofluorescence Immunologic;Immunohistochemistry;In Situ;Institution;Laboratories;Leadership;Lung;Measurement;member;Methods;molecular marker;operation;participant enrollment;Pathology;Patients;Physicians;Policies;Procedures;Proteins;Research;Research Personnel;Resource Sharing;Resources;Retrieval;RNA;Safety;sample fixation;Scanning;Series;Services;Shipping;Slide;Surgical Pathology;System;Therapeutic;Tissue Banks;tissue fixing;Tissue Microarray;Tissue Sample;Tissues;transcriptome;Translational Research;Universities;Update;Work;Yale Cancer Center

PROJECT_TITLE: Yale Pathology Tissue Services Shared Resource


ADMINISTERING_IC: OD

ED_INST_TYPE: SCHOOLS OF VETERINARY MEDICINE

IC_NAME: OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH

ORG_CITY: COLUMBIA

ORG_DEPT: VETERINARY SCIENCES

ORG_NAME: UNIVERSITY OF MISSOURI-COLUMBIA

ORG_STATE: MO

PHR: Project Narrative (Overall) Rats are instrumental for the understanding of human disease and they play an important role in the development of drugs and therapeutics. The Rat Resource and Research Center provides a unique centralized repository for importing, storing and distributing a large number of rat strains, embryonic stem cells and related reagents. The RRRC also provides critical services to assist biomedical researchers and performs innovative research to ensure the quality, reproducibility and availability of rat models.

PI_NAMEs: BRYDA, ELIZABETH C (contact)

PROGRAM_OFFICER_NAME: MIROCHNITCHENKO, OLEG

PROJECT_TERMS: Animal Model;Animals;Applied Research;Archives;Area;assay development;Behavioral;Biological Process;Biomedical Research;biomedical resource;Cardiovascular system;Communication;Communities;Consultations;cost;cost effective;COVID-19 pandemic;CRISPR/Cas technology;Cryopreservation;Cytogenetics;Derivation procedure;Disease;drug development;Embryo;embryonic stem cell;Ensure;ES Cell Line;Fee-for-Service Plans;Fertilization in Vitro;functional improvement;Gene Modified;Generations;Genetic;genetic analysis;Genetic Engineering;genome editing;Goals;Health;human disease;human model;improved;Individual;innovation;Institution;interest;Knock-out;Methods;microbiota;Mission;model development;model organism;Modeling;Modification;Monitor;mouse model;Mus;Physiology;Play;preservation;Process;Protocols documentation;Quality Control;rat genome;Rat Strains;Rattus;Reagent;repository;Reproducibility;Reproductive Biology;Research;Research Personnel;Resource Sharing;Resources;Rodent Model;Role;service delivery;Services;Spectral Karyotyping;sperm cell;sperm cryopreservation;Sperm Motility;Sperm Preservation;stem;Technology;Therapeutic;Time;Tissues;Toxicology;United States;United States National Institutes of Health;Vendor

PROJECT_TITLE: Rat Resource and Research Center

STUDY_SECTION_NAME: Special Emphasis Panel[ZRG1 MGG-E (55)]


PHR: PROJECT NARRATIVE The addition of a Curation and Informatics Section will provide necessary dedicated personnel and infrastructure to maintain and improve the RRRC website, ordering system and internal databases as well as ensure that data associated with the holdings of the RRRC are well curated. This will enhance RRRC operations and improve the experience of RRRC users.

PROJECT_TERMS: Achievement;Animals;Biocompatible Materials;Biomedical Research;Collaborations;Communities;Custom;Data;Data Coordinating Center;data curation;data dissemination;Data Management Resources;Databases;Dedications;Development;Electronics;embryonic stem cell;Ensure;experience;FAIR principles;Friends;Genetic;Goals;Health;Human Resources;improved;Individual;Informatics;Information Management;Infrastructure;interest;Link;Marketing;Methods;Mission;Modeling;Monitor;operation;Outcome;Play;Practice Management;preservation;programs;Protocols documentation;Qualifying;Quality Control;Rat Genome Database;Rat Strains;Rattus;Reagent;Reporting;repository;Reproducibility;Research;Research Personnel;Resource Sharing;Resources;Role;Services;Site;Surveys;System;TRUST principles;United States National Institutes of Health;Update;user-friendly;web site;Work

PROJECT_TITLE: Curation and Informatics


FUNDING_MECHANISM: NON-SBIR/STTR RPGS

NIH_SPENDING_CATS: Behavioral and Social Science;Biotechnology;Cancer;Clinical Research;Clinical Trials and Supportive Activities;Gene Therapy;Gene Therapy Clinical Trials;Genetics;Health Disparities Research;Health Disparities and Racial or Ethnic Minority Health Research;Health Services;Hematology;Immunotherapy;Mental Health;Orphan Drug;Patient Safety;Rare Diseases;Social Determinants of Health

ORG_CITY: TAMPA

ORG_NAME: H. LEE MOFFITT CANCER CTR & RES INST

ORG_STATE: FL

PHR: PROJECT NARRATIVE Chimeric antigen receptor T-cell therapy (CAR T) is revolutionizing the treatment of relapsed/refractory multiple myeloma (RRMM) and offering new hope to a growing population living with incurable cancer; however, survivorship outcomes for patients treated in standard of care settings remain unknown. This study will establish a first-in-kind resource of highly characterized and diverse RRMM patients treated with standard of care CAR T, with systematic assessments of patient-reported outcomes and biospecimen samples, to identify psychosocial and immune-related factors associated with key survivorship outcomes. Findings from this study will have direct implications for developing and implementing patient education materials, clinical decision-making tools, and supportive care interventions to improve RRMM survivorship outcomes after CAR T.

PI_NAMEs: HANSEN, DORIS K;OSWALD, LAURA B. (contact);PERES, LAUREN COLE

PROGRAM_OFFICER_NAME: GALLICCHIO, LISA M

PROJECT_TERMS: Address;Anxiety;anxiety symptoms;Behavioral;Blood specimen;Bone Marrow;C-reactive protein;cancer cell;Cancer Center;Cancer Survivorship;CAR T cell therapy;CD3 Antigens;Cells;Clinical;clinical decision-making;Clinical Trials;Data;depressive symptoms;Development;Disease;Disease remission;Educational Materials;Eligibility Determination;ethnic disparity;ethnic diversity;evidence base;exhaustion;experience;FDA approved;Ferritin;Goals;health related quality of life;Hematologic Neoplasms;Immune;Immune system;Immunofluorescence Immunologic;Immunologic Markers;improved;Incidence;Inflammation;Infusion procedures;Institution;Interleukin-6;Intervention;Life;Malignant Neoplasms;Mediating;Mental Depression;Multiple Myeloma;Not Hispanic or Latino;novel;Outcome;Outcome Assessment;Participant;Patient Education;Patient Outcomes Assessments;Patient Schedules;Patient-Focused Outcomes;Patients;Pharmaceutical Preparations;Phenotype;Population;programmed cell death protein 1;Progression-Free Survivals;Prospective cohort;Psychoneuroimmunology;psychosocial;Psychosocial Factor;psychosocial stressors;racial disparity;racial diversity;Recurrent disease;Refractory;Refractory Disease;Relapse;Reporting;Research;Resources;Sampling;Severities;social deficits;Social support;spatial relationship;Stains;standard of care;Statistical Methods;study population;Supportive care;survivorship;Symptom Burden;systemic inflammatory response;T-Lymphocyte;Time;tool;Toxic effect;treatment response;Treatment-related toxicity;tumor-immune system interactions;virtual;Work

PROJECT_TITLE: Survivorship in Patients with Multiple Myeloma Treated with Chimeric Antigen Receptor T-cell Therapy

STUDY_SECTION_NAME: Special Emphasis Panel[ZCA1 SRB-2 (M1)]


ADMINISTERING_IC: EY

IC_NAME: NATIONAL EYE INSTITUTE

NIH_SPENDING_CATS: Brain Disorders;Eye Disease and Disorders of Vision;Fragile X Syndrome;Intellectual and Developmental Disabilities (IDD);Neurosciences;Pediatric;Rare Diseases

ORG_CITY: WASHINGTON

ORG_NAME: CHILDREN'S RESEARCH INSTITUTE

ORG_STATE: DC

PHR: NARRATIVE Unchanged from parent grant.

PI_NAMEs: TRIPLETT, JASON  (contact)

PROGRAM_OFFICER_NAME: CLAYTON, EDWIN C

PROJECT_TERMS: Address;anatomical tracing;area striata;career;Communication;Data;Data Analyses;Development;effective therapy;Electrophysiology (science);Etiology;Eye;Fragile X Syndrome;Functional disorder;Genetic;Health;in vivo;insight;Instinct;Knowledge;Learning;Maps;Methods;Modeling;mouse model;Mus;Neurodevelopmental Disorder;Neurons;novel;parent grant;Parents;Research;Retinal Ganglion Cells;Role;Sensory;skills;Specificity;superior colliculus Corpora quadrigemina;Synapses;Techniques;Testing;training opportunity;Visual;visual map;Visual System

PROJECT_TITLE: Mechanisms of Synaptic Specificity in Visual Circuits


ADMINISTERING_IC: AI

ED_INST_TYPE: SCHOOLS OF MEDICINE

FUNDING_MECHANISM: TRAINING, INSTITUTIONAL

IC_NAME: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

ORG_CITY: ATLANTA

ORG_DEPT: INTERNAL MEDICINE/MEDICINE

ORG_NAME: EMORY UNIVERSITY

ORG_STATE: GA

PHR: Narrative The Emory VTP-T32 addresses the urgent need for training the next generation of vaccinologists. Vaccines have dramatically reduced the burden of infectious diseases, shown great potential for preventing and controlling conditions, and often are highly cost-effective. However, to achieve the full potential of vaccines and address difficulties that have hindered progress, a new generation of well-prepared scientists continues to be needed.

PI_NAMEs: AMARA, RAMA RAO ;LOPMAN, BENJAMIN A;ROUPHAEL, NADINE GEORGES (contact)

PROGRAM_OFFICER_NAME: SASTALLA, INKA I

PROJECT_TERMS: Generations;Training

PROJECT_TITLE: Training a new generation of vaccinologists

STUDY_SECTION: MID

STUDY_SECTION_NAME: Microbiology and Infectious Diseases Research Study Section[MID]


ADMINISTERING_IC: AG

ED_INST_TYPE: HOSPITALS

IC_NAME: NATIONAL INSTITUTE ON AGING

NIH_SPENDING_CATS: Acquired Cognitive Impairment;Aging;Alzheimer's Disease;Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD);Basic Behavioral and Social Science;Behavioral and Social Science;Brain Disorders;Dementia;Infectious Diseases;Neurodegenerative;Neurosciences

ORG_CITY: HOUSTON

ORG_NAME: UNIVERSITY OF TX MD ANDERSON CAN CTR

ORG_STATE: TX

PHR: Project Narrative The proposed studies aim to develop squirrel monkeys, rhesus monkeys, baboons, and chimpanzees as a well-defined immunological model to target immunosenescence. We plan to investigate the relationship between immunosenescence and both neurodegeneration and cognition across these species with differing lifespans. The differences within and between species may elucidate differences within human populations and can lead to the development of interventions aimed toward improving longevity.

PI_NAMEs: MULHOLLAND, MICHELE M (contact)

PROGRAM_OFFICER_NAME: FRANKOWSKI, DAVID WITT

PROJECT_TERMS: Adaptive Immune System;adaptive immunity;Adipose tissue;Age;age group;Age of Onset;age related;age related changes;age related decline;Aging;aging biomarker;aging brain;aging process;Alzheimer's disease pathology;Amyloid beta-Protein;Antibodies;Antigen Presentation;Antigens;Autoimmunity;B-Lymphocytes;Binding;Biological Markers;Biological Process;Blood;Brain-Derived Neurotrophic Factor;C-reactive protein;CD28 gene;CD4/CD8 ratio procedure;CD8B1 gene;Cell Physiology;Cells;Cellular Immunity;chemokine;CHI3L1 gene;Chronic;Chronic Disease;Ciliary Neurotrophic Factor;Clinical;Cognition;cognitive function;cognitive performance;cognitive task;cognitive testing;Communicable Diseases;Complex;cytokine;cytotoxic;design;Disease;early onset;FCGR3B gene;FGF21 gene;fibroblast growth factor 21;Frequencies;glial cell-line derived neurotrophic factor;Glial Fibrillary Acidic Protein;Goals;healthspan;Helper-Inducer T-Lymphocyte;Human;Humoral Immunities;Immune;immune function;Immune system;immune system function;Immunity;Immunological Models;immunosenescence;Impaired cognition;improved;in vivo;Incidence;Individual;Inflammaging;Inflammation;Inflammatory;inflammatory marker;innate immune function;Innate Immune System;interest;Interleukin-1;Interleukin-10;Interleukin-6;Kinetics;Kininogenase;Life Expectancy;life span;Longevity;Macaca mulatta;Macrophage;Malignant Neoplasms;Measures;Mediating;Memory;Minor;Molecular;Monitor;Monkeys;Natural Immunity;Natural Killer Cells;NCAM1 gene;Nerve Degeneration;Neurofilament-H;neurogranin;Neurologic;Neurosciences;neutrophil;nonhuman primate;older adult;Pan Genus;Papio;Papio anubis;pathogen;Peptides;Phenotype;Plasma;Play;Population;Positron-Emission Tomography;Process;protein TDP-43;Regulation;Research Personnel;response;Rhesus;Risk Factors;Role;Saimiri;Sampling;Series;Severities;stem;stem cells;Surface;System;T cell regulation;T cell response;T-Cell Receptor;T-Lymphocyte;T-Lymphocyte Subsets;tau Proteins;Testing;therapy development;Thymus Gland;TNF gene;TNFRSF6 gene;UCHL1 gene

PROJECT_TITLE: Relationships between immunosenescence, brain aging biomarkers, and cognition across nonhuman primate species of differing lifespans

STUDY_SECTION_NAME: Special Emphasis Panel[ZAG1 ZIJ-3 (M1)]


ORG_CITY: BOSTON

ORG_NAME: DANA-FARBER CANCER INST

ORG_STATE: MA

PHR: PROJECT NARRATIVE Research investigation in population science is essential to ensure that discoveries from molecular medicine and clinical trials translate to routine practice and ultimately decrease the population-level burden of cancer. The Dana-Farber Harvard Cancer Center’s (DF/HCC) T32 Training in Oncology Population Sciences (TOPS) program equips postdoctoral fellows with the skills necessary to evaluate cancer care quality and effectiveness, and to develop, test and implement interventions to improve care delivery thereby ensuring that T1/T2 discoveries translate across the T3/T4 bridge to achieve maximal impact on population health. Postdoctoral fellows pursue a two-year program of mentored research, coursework and professional skills training that supports innovation and leverages the expertise of DF/HCC faculty to prepare them for independent investigation in cancer-focused population science.

PI_NAMEs: KEATING, NANCY L;MACK, JENNIFER W (contact)

PROGRAM_OFFICER_NAME: LIM, SUSAN E

PROJECT_TERMS: Oncology;Population Sciences;Training

STUDY_SECTION_NAME: Institutional Training and Education Study Section (F)[NCI-F]


ADMINISTERING_IC: GM

ED_INST_TYPE: SCHOOLS OF ARTS AND SCIENCES

IC_NAME: NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES

NIH_SPENDING_CATS: Behavioral and Social Science

ORG_CITY: Bayside

ORG_DEPT: BIOLOGY

ORG_NAME: QUEENSBOROUGH COMMUNITY COLLEGE

ORG_STATE: NY

PHR: Project Narrative: T34 Training Program at Queensborough Community College (QCC) Ghoshal, Sarbani Project Narrative QCC’s Bridges Program is a collaborative endeavor that engineers a comprehensive system of academic, research, mentoring, and career development support to empower research-oriented students, particularly from underrepresented minorities, to transition to biomedical baccalaureate programs.

PI_NAMEs: GHOSHAL, SARBANI  (contact);PATHAK, SANJAI KUMAR;STARK, RUTH E.

PROGRAM_OFFICER_NAME: STEPANEK, LAURIE ELIZABETH

PROJECT_TERMS: Academic support;Awareness;Biology;Biomedical Research;bridge to the baccalaureate;broadening participation research;Cancer Education Grant Program;career;career development;Chemistry;Cities;college;Communication;Communities;community college;Counseling;Development;Diverse Workforce;Educational Curriculum;Educational process of instructing;Educational workshop;experience;faculty mentor;Goals;graduate student;Howard Temin Award;improved;Institution;interest;Laboratory Research;Learning;Mathematics;Mentors;Oral;Outcomes Research;Participant;Pathway interactions;pedagogy;peer coaching;Physics;precalculus;programs;Psychosocial Assessment and Care;Recording of previous events;Recruitment Activity;Reporting;Research;Research Training;role model;Science;skill acquisition;skills;STEM field;student participation;Students;success;Supervision;System;Teacher Professional Development;Technology;Text;Training;Training Programs;undergraduate research;Underrepresented Populations;United States National Institutes of Health;Update;Work;Writing

PROJECT_TITLE: Bridges to Baccalaureate program at Queensborough Community College

STUDY_SECTION: TWD

STUDY_SECTION_NAME: Training and Workforce Development Study Section - C[TWD-C]


NIH_SPENDING_CATS: Acquired Cognitive Impairment;Aging;Alzheimer's Disease;Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD);Basic Behavioral and Social Science;Behavioral and Social Science;Brain Disorders;Cerebrovascular;Dementia;Digestive Diseases;Mental Health;Microbiome;Neurodegenerative;Neurosciences;Physical Injury - Accidents and Adverse Effects

ORG_CITY: Aurora

ORG_DEPT: SURGERY

ORG_NAME: UNIVERSITY OF COLORADO DENVER

ORG_STATE: CO

PHR: Narrative Alzheimer's Disease (AD) and AD related disorders (ADRD) are progressive neurologic disorders primarily affecting the elderly. Damaging more than just the skin, burn injuries can lead to excessive inflammation that often involves multiple organs systems including leakiness of the protective barriers of the gut and the brain, leading to aberrant cognitive function including delirium and dementia, which may parallel the changes seen in AD/ADRD. By investigating age-related mechanisms responsible for early damage to the gut and blood brain barriers after burn injury, we hope to identify novel strategies to reduce the impact of this post-injury neuroinflammation and mental decline seen in elderly subjects suffering from a wide range of diseases, including AD/ADRD.

PI_NAMEs: KOVACS, ELIZABETH J. (contact)

PROGRAM_OFFICER_NAME: TILAHUN, MULUALEM ENYEW

PROJECT_TERMS: Administrative Supplement;Affect;Age;age related;aged;Aging;aging population;Alzheimer's Disease;Alzheimer's disease related dementia;Astrocytes;Bacteria;Bacterial Translocation;behavior test;Biological Markers;Blood - brain barrier anatomy;Blood brain barrier dysfunction;blood-brain barrier permeabilization;Body System;Brain;Brain region;Burn injury;Burn Trauma;CCL2 gene;Cell Wall;Cessation of life;chemokine;Circulation;Clinical;Clinical Research;clinically relevant;Cognition;cognitive function;commensal bacteria;Confusion;Cutaneous;Cyclic AMP-Responsive DNA-Binding Protein;cytokine;cytokine release syndrome;Delirium;Dementia;dentate gyrus;Development;Disease;Distant;Elderly;Environmental Risk Factor;Exhibits;experimental study;Exposure to;fecal microbiome;Functional disorder;Funding;Glial Fibrillary Acidic Protein;Goals;gut microbiome;gut-brain axis;Health;Hippocampus;Impaired cognition;Impairment;Incidence;Infection;Inflammaging;Inflammation;Inflammation Mediators;Inflammatory;inflammatory marker;Inflammatory Response;injured;Injury;Interleukin-1;Interleukin-1 beta;Interleukin-6;intestinal barrier;intestinal epithelium;Intestinal permeability;Intestines;Ischemic Bowel Disease;Knowledge;Leaky Gut;Ligands;Lipopolysaccharides;Macrophage;Mediating;Mediator;Memory;mental state;microbiome;microbiome composition;Microglia;Monitor;mouse model;mRNA Expression;Mucous Membrane;Mus;Nervous System Disorder;Nervous System Physiology;Neurocognitive;Neurocognitive Deficit;Neurodegenerative Disorders;neuroinflammation;Neurologic;Neurons;novel strategies;novel therapeutics;old mice;older patient;Organ;Organ failure;Outcome;Pathogenesis;Patients;Persons;Phosphorylation;Play;prevent;Production;Proteins;Psyche structure;Publishing;Research;response;Role;Severities;Skin;Small Intestines;Stimulus;systemic inflammatory response;Testing;Tight Junctions;Time;tissue injury;tissue repair;TNF gene;Trauma;Traumatic injury;United States;Work

PROJECT_TITLE: Aging, macrophage mediators, and burn trauma: Supplement

STUDY_SECTION: ASG

STUDY_SECTION_NAME: Aging Systems and Geriatrics Study Section[ASG]


NIH_SPENDING_CATS: Acquired Cognitive Impairment;Aging;Alzheimer's Disease;Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD);Brain Disorders;Data Science;Dementia;Networking and Information Technology R&D (NITRD);Neurodegenerative;Neurosciences

ORG_DEPT: PHARMACOLOGY

PHR: Narrative Given the large number of “big data” initiatives (i.e., “-omics studies) in the Alzheimer’s disease research space and their potential transformative power, we propose a new pre- and post-doctoral training program designed to bridge gaps between “big data” science and more focused hypothesis-driven biological studies that establish causal relationships. This training grant will prepare a next generation of scientists to move the field forward by leveraging both big data initiatives and more fundamental scientific approaches.

PI_NAMEs: GOLDE, TODD E (contact);WEINSHENKER, DAVID

PROGRAM_OFFICER_NAME: LUO, YUAN

PROJECT_TERMS: Alzheimer's Disease;Big Data;Biology;Training Programs

PROJECT_TITLE: Alzheimer's Disease Big Data to Biology Training Program (ADBDB-TP)

STUDY_SECTION: AGCD

STUDY_SECTION_NAME: Career Development for Established Investigators and Conference Grants Study Section[AGCD-4]


ED_INST_TYPE: BIOMED ENGR/COL ENGR/ENGR STA

NIH_SPENDING_CATS: Acquired Cognitive Impairment;Aging;Alzheimer's Disease;Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD);Brain Disorders;Dementia;Neurodegenerative;Neurosciences

ORG_CITY: TEMPE

ORG_DEPT: BIOMEDICAL ENGINEERING

ORG_NAME: ARIZONA STATE UNIVERSITY-TEMPE CAMPUS

ORG_STATE: AZ

PHR: PROJECT NARRATIVE Early detection of Alzheimer’s Disease and Related Dementia (AD/ADRD) makes it possible for initiation of early intervention, its assessment (preventive clinical trials) to slow down the progression, even prevent the onset and reduce care costs. Leveraging unique AD/ADRD resources in Arizona including the Arizona Alzheimer’s Consortium (AAC) and Mirabella - a senior living community on the Arizona State University campus, we propose to train pre-doctoral researchers with an Artificial Intelligence (AI) mindset when attacking long-standing challenges in AD/ADRD research including clinical science, diagnostics and engineering, disease biology, data science, and drug discovery/development. This novel integration provides the opportunity not only for intergenerational education but also for community defined field research projects in the training program.

PI_NAMEs: KLEIN, JUDITH ;LI, BAOXIN ;VELAZQUEZ, RAMON ;WU, TERESA  (contact)

PROJECT_TITLE: Intergenerational Community Driven Training in Alzheimer's Disease Research: An AI+X Approach


ADMINISTERING_IC: HL

IC_NAME: NATIONAL HEART, LUNG, AND BLOOD INSTITUTE

ORG_CITY: MILWAUKEE

ORG_NAME: VERSITI WISCONSIN, INC.

ORG_STATE: WI

PHR: OVERALL COMPONENT – PROJECT NARRATIVE  This is a revised application for a Program Project Grant seeking to provide support for a coordinated, multi- disciplinary investigation of the molecular mechanisms that underly clinically relevant immune-mediated thrombocytopenic disorders that are of importance to clinicians, scientists, and patients alike. The central unifying theme of our application is to develop a deep understanding of a wide range of immunological insults that lead to thrombocytopenia and downstream sequelae in the fetus, newborn, and adults. The Program takes place at the Versiti Blood Research Institute of Versiti's Blood Center of Wisconsin - a nationally renowned facility strictly focused on and devoted to all aspects of blood-related research, including transfusion medicine, hematology, and immunobiology, and within the Pediatric Hematology Division of Children's Hospital of Philadelphia - an elite scientific research institution located on a premier academic medical campus.

PI_NAMEs: NEWMAN, PETER J (contact)

PROGRAM_OFFICER_NAME: KINDZELSKI, ANDREI L

PROJECT_TERMS: academic program;Acute;Address;Adenoviruses;Adult;Affect;Alloantigen;Alloimmunization;Antibodies;Antigens;Area;Autoantigens;B-Lymphocytes;Binding;Biological Assay;Blood;Blood Coagulation Disorders;Blood Platelets;cell growth regulation;cell injury;cell type;Characteristics;chemokine;Chronic;Clinical;clinically relevant;Cloning;Collaborations;COVID-19 vaccine;Cytoplasmic Granules;design;Development;Diagnosis;Diagnostic;Discipline;Disease;Endothelial Cells;Etiology;experience;fascinate;Fertilization;fetal;Fetus;Funding;Future;Germ-Free;gut bacteria;gut microbiome;Health;Hematology;Hemostatic function;Heparin;heparin-induced thrombocytopenia;Human;Idiopathic Thrombocytopenic Purpura;Immune;Immune System Diseases;Immunobiology;Immunologics;Immunology;immunoreaction;improved;innovation;insight;Institution;Integrins;interest;Investigation;Knowledge;Life;man;Maternal antibody;Mediating;Medical;Medicine;Mission;Molds;Molecular;Monoclonal Antibodies;mouse model;multidisciplinary;Mus;National Heart, Lung, and Blood Institute;Neonatal;Neonatal Alloimmune Thrombocytopenia;neonate;Newborn Infant;novel;Outcome;Pathogenesis;Pathogenicity;Pathology;Patients;Pediatric Hematology;Pediatric Hospitals;PF4 Gene;Pharmacologic Substance;Philadelphia;Physiology;Plasma;Platelet Activation;Population;PPBP gene;pre-clinical;Pregnancy;prevent;Prevention;Productivity;Program Research Project Grants;programs;prophylactic;Reagent;Recommendation;Recording of previous events;Research;Research Institute;Research Personnel;Resources;response;Role;Route;SARS-CoV-2 infection;Science;Scientist;screening;Severities;side effect;Sum;Techniques;Therapeutic;Thrombocytopenia;Thrombosis;thrombotic;Transfusion;transfusion medicine;Transplantation;Vaccine Design;Vaccines;Wisconsin

PROJECT_TITLE: Molecular Mechanisms of Immune Thrombocytopenia in Transfusion Medicine

STUDY_SECTION: HLBP

STUDY_SECTION_NAME: Heart, Lung, and Blood Program Project Study Section[HLBP (MA)]


PROJECT_TERMS: Advisory Committees;arm;Blood;Doctor of Philosophy;Ensure;Environment;Equipment;Idiopathic Thrombocytopenic Purpura;Leadership;meetings;Molecular;Participant;Principal Investigator;programs;Research;Research Institute;Research Personnel;Schedule;Supervision;transfusion medicine;Wisconsin

PROJECT_TITLE: Administrative Core A


NIH_SPENDING_CATS: Autoimmune Disease;Biotechnology;Genetics;Hematology;Human Genome;Immunization;Pediatric;Perinatal Period - Conditions Originating in Perinatal Period;Preterm, Low Birth Weight and Health of the Newborn;Prevention;Rare Diseases;Vaccine Related

PI_NAMEs: ZHU, JIEQING  (contact)

PROJECT_TERMS: Adenoviruses;Antibodies;Antibody Formation;Antigen Targeting;Antigens;B-Lymphocytes;Biochemical;Bioinformatics;Biological Assay;Blood Platelets;Cell Line;Cells;chemokine;Clinical;Collaborations;Complex;Cost Savings;Crystallography;Data;Data Analyses;database structure;Disease;Electron Microscopy;Ensure;Escherichia coli;experimental study;fetal;Goals;Growth;gut microbiota;heparin-induced thrombocytopenia;Human;Hybridomas;Idiopathic Thrombocytopenic Purpura;Immune;Immunize;Immunoglobulins;Insecta;Integrins;ITGB3 gene;light scattering;Link;Mammalian Cell;Measures;Mediating;Molecular;Monoclonal Antibodies;Mus;mutant;Neonatal Alloimmune Thrombocytopenia;next generation sequencing;Nucleic acid sequencing;Pathogenesis;PF4 Gene;PPBP gene;Production;programs;Protein Isoforms;Proteins;Protocols documentation;Reagent;Recombinants;Reproducibility;Research;Resolution;Ribosomal RNA;Services;Shotgun Sequencing;single-cell RNA sequencing;Standardization;structural biology;Structure;Technology;Thrombocytopenia;Thrombosis;thrombotic;Time;tool;transcriptome sequencing;transfusion medicine;Vaccines;Validation;Variant

PROJECT_TITLE: Protein Production, Structural Biology, and Nucleic Acid Sequencing and Analysis


NIH_SPENDING_CATS: Autoimmune Disease;Brain Disorders;Clinical Research;Hematology;Maternal Health;Pediatric;Perinatal Period - Conditions Originating in Perinatal Period;Pregnancy;Preterm, Low Birth Weight and Health of the Newborn;Prevention;Rare Diseases;Women's Health Research

PHR: PROJECT NARRATIVE  Platelets circulate in the bloodstream and, when they encounter a damaged blood vessel, become activated and stick together to help to plug up the damaged area and stop bleeding; excessive bleeding occurs when platelet counts are too low, which is a condition referred to as thrombocytopenia. This application represents a unique application of hematology and immunology expertise required to tackle unresolved problems in the immunologic bleeding disorder Fetal/Neonatal Alloimmune Thrombocytopenia (FNAIT), which is a non- malignant hematologic disease that arises when the immune system of a pregnant woman makes antibodies that clear a baby's platelets before or immediately after birth. We are especially interested in determining why FNAIT develops in some at-risk pregnancies, but not others, and why some babies with FNAIT experience excessive bleeding in the brain, referred to as intracranial hemorrhage, which can result in irreversible brain damage and death.

PROJECT_TERMS: Address;Affect;Alloantigen;Alloimmunization;Animal Model;Antibodies;Antigens;Area;at-risk pregnancies;Binding;Biological Assay;Birth;Blood Circulation;Blood Coagulation Disorders;blood damage;Blood Platelets;Blood Vessels;Brain Death;Brain hemorrhage;Brain Injuries;cell injury;Cells;Circulation;Clinical;clinical application;clinically relevant;clinically significant;Complex;Development;Diagnosis;diagnostic value;dimorphism;Disease;Distant;Dose;EGF gene;Endothelial Cells;Epitopes;Erythrocytes;Etiology;European;Event;experience;fetal;Fetal Diseases;Fetus;fetus cell;First Pregnancy Trimester;Generations;Genetic Polymorphism;Goals;Hematological Disease;Hematology;Hemorrhage;Hemorrhagic Complication of Pregnancy;Heterogeneity;Human;Human Platelet Antigens;Idiopathic Thrombocytopenic Purpura;Immune;Immune system;Immunobiology;Immunologics;Immunology;improved;In Vitro;in vivo;indexing;Infant;Inherited;innovation;insight;Integrins;interest;Intracranial Hemorrhages;Isoantibodies;Knowledge;Laboratories;Lead;Leucine;Life;Live Birth;Maternal antibody;Measures;Membrane Glycoproteins;Molecular;mouse model;Mus;Neonatal;Neonatal Alloimmune Thrombocytopenia;neonatal period;Newborn Infant;Non-Malignant;novel;Organ;Persons;Placenta;placental trophoblasts;Platelet Count measurement;platelet function;Platelet Membrane Glycoproteins;pre-clinical;Pregnancy;Pregnancy Complications;Pregnancy loss;Pregnant Women;prevent;Prevention strategy;Production;Property;prophylactic;Protein Structure Initiative;Recommendation;Reporting;Resolution;response;Route;Series;Severities;Specificity;Technology;Testing;Thrombocytopenia;Time;transfusion medicine;Transgenic Organisms;treatment strategy;Wild Type Mouse

PROJECT_TITLE: The Immunobiology of Fetal/Neonatal Alloimmune Thrombocytopenia


NIH_SPENDING_CATS: Autoimmune Disease;Biotechnology;Cardiovascular;Clinical Research;Hematology;Microbiome;Prevention;Rare Diseases

PHR: NARRATIVE  Heparin-induced thrombocytopenia (HIT) is an adverse immune reaction resulting from antibodies targeting platelet factor 4 (PF4) bound to heparin, causing morbidity and mortality in patients undergoing heparin treatment. This research characterizes the interactions between HIT antibodies and PF4/heparin complexes, as well as identifies gut microbiota species associated with the generation of HIT antibodies. These findings will offer new insights into the pathogenesis of HIT, impacting its diagnosis, prevention, and treatment.

PI_NAMEs: WEN, RENREN  (contact)

PROJECT_TERMS: 16S ribosomal RNA sequencing;Address;Antibodies;Antibody Formation;B-Lymphocytes;Bacteria;Bacterial Infections;Binding;Biochemical;Biological;Biological Assay;biophysical techniques;Blood Platelets;Cells;Characteristics;Clinical;Clone Cells;Cloning;Collaborations;complementarity-determining region 3;Complex;cost;Coupled;Development;Diagnosis;Diagnostic tests;Disease;Electrostatics;Epitopes;Etiology;Exhibits;Failure;Fertilization;Frequencies;Future;Generations;Germ-Free;Glycosaminoglycans;Goals;gut bacteria;gut microbes;gut microbiome;gut microbiota;Heparin;heparin-induced thrombocytopenia;Human;Idiopathic Thrombocytopenic Purpura;IgG1;Immune system;Immunobiology;Immunoglobulin G;Immunoglobulin M;immunoreaction;Individual;Inflammation;innovation;insight;interest;Knowledge;Length of Stay;Link;man;Mediating;microbial;Molecular;Monoclonal Antibodies;Morbidity - disease rate;mortality;Mus;Mutagenesis;novel;Pathogenesis;Pathogenicity;Patients;Peripheral;personalized diagnostics;PF4 Gene;Platelet Activation;Platelet Count measurement;Platelet Function Tests;prevent;Prevention;Probability;Production;programs;Property;Rapid diagnostics;reconstitution;Reporting;Research;Resources;Ribosomal RNA;Risk;Role;screening;Shapes;Shotgun Sequencing;side effect;Surface;Surface Antigens;Symptoms;System;Testing;Thrombocytopenia;Thromboembolism;Thrombosis;transfusion medicine;Venous

PROJECT_TITLE: The Immunobiology of Heparin-Induced Thrombocytopenia


NIH_SPENDING_CATS: Autoimmune Disease;Biodefense and Related Countermeasures;Biotechnology;Cardiovascular;Clinical Research;Coronaviruses;Coronaviruses Vaccines;Emerging Infectious Diseases;Hematology;Immunization;Infectious Diseases;Orphan Drug;Prevention;Rare Diseases;Vaccine Related

PHR: NARRATIVE  Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a rare, life-threatening clotting complication of the Johnson & Johnson and AstraZeneca vaccines for COVID-19. How VITT causes clotting that can lead to death even with modern day treatments is not known. We have discovered new proteins called chemokines that may be important in causing the clotting and believe that our studies may help find new medicines to treat VITT and other situations where people clot too much.

PI_NAMEs: PONCZ, MORTIMER  (contact)

PROJECT_TERMS: Adenoviruses;Adjuvant;Alanine;Amino Acid Sequence;Amino Acid Substitution;Amino Acids;Antibodies;arteriole;AstraZeneca COVID-19 vaccine;Binding;Binding Sites;Blood;Blood Platelets;Carotid Arteries;Cessation of life;chemokine;chemokine receptor;Clinical;Coagulation Process;Complex;Complication;COVID-19 vaccination;Cytoplasmic Granules;Data;Deaminase;Development;Diagnosis;Diagnostic;Disease;Endothelium;Enzyme-Linked Immunosorbent Assay;extracellular;Femoral vein;Heparin;Heparin Binding;heparin-induced thrombocytopenia;Human;Idiopathic Thrombocytopenic Purpura;IL8RB gene;Immune;Immunobiology;Immunoglobulin G;In Vitro;in vivo;injured;insight;Interleukin-8B Receptor;Intramuscular;Knock-out;Knockout Mice;Laser injury;Life;light scattering;Medicine;Microfluidics;Modeling;Modernization;Modification;Molecular;Monoclonal Antibodies;mouse model;Mus;Mutagenesis;N-terminal;Nature;neutrophil;novel;novel vaccines;optimal treatments;Outcome;Patients;Persons;PF4 Gene;Plasma;Plasma Enhancement;PPBP gene;programs;Protein Isoforms;Proteins;Publishing;Reaction;Research;Research Institute;Reverse engineering;Risk;Role;Rose Bengal;Safety;SARS-CoV-2 infection;SARS-CoV-2 spike protein;Scanning;Site;Structure;synergism;Testing;Therapeutic;Thrombocytopenia;Thrombosis;thrombotic;thrombotic complications;Thrombus;Time;transfusion medicine;Transgenic Organisms;treatment duration;Vaccination;vaccination outcome;vaccine development;vaccine safety;vaccine strategy;Vaccinee;Vaccines;Venous;venule;Vertebral column

PROJECT_TITLE: The Immunobiology of Vaccine-induced Immune Thrombotic Thrombocytopenia


NIH_SPENDING_CATS: Biodefense and Related Countermeasures;Emerging Infectious Diseases;Genetics;Infectious Diseases;Rare Diseases;Vector-Borne Diseases

ORG_CITY: AMES

ORG_NAME: IOWA STATE UNIVERSITY

ORG_STATE: IA

PHR: This project will identify the precise genomic determinants and molecular mechanisms that condition the differential host ranges of insect-specific and mosquito/vertebrate flaviviruses, providing information that will assist in the rationale design of novel intervention strategies to control flavivirus transmission and disease.

PI_NAMEs: BLITVICH, BRADLEY J (contact)

PROGRAM_OFFICER_NAME: GAUTAM, RAJEEV

PROJECT_TERMS: 3' Untranslated Regions;5' Untranslated Regions;Applications Grants;Arthropods;Binding;Binding Proteins;Biotin;Biotinylation;Capsid Proteins;Cell Culture Techniques;Cells;Chimera organism;Complex;Culicidae;Data;Dengue Virus;design;Detection;Disease;DNA-Directed RNA Polymerase;Elements;experimental study;Flavivirus;Funding;Genes;Genetic;Genetic Determinism;Genome;Genomics;Goals;helicase;Human;human pathogen;Immunoprecipitation;Insecta;insight;interest;Intervention;Japanese encephalitis virus;knock-down;Label;liquid chromatography mass spectrometry;Mass Spectrum Analysis;Mediating;Molecular;Mosquito Control;mosquito-borne;novel;overexpression;Phenotype;Phylogenetic Analysis;protein crosslink;Proteins;Public Health;RNA;RNA Interference;RNA-Binding Proteins;RNA-Protein Interaction;Serotyping;Specificity;stem;Streptavidin;Structure;Techniques;Ticks;transcriptome sequencing;Transfection;transmission process;Tropism;Untranslated Regions;Vertebrates;Viral;Viral Genome;viral RNA;Virus;virus host interaction;Virus Replication;West Nile virus;Yellow fever virus;Zika Virus

PROJECT_TITLE: Identification of the untranslated sequence elements and virus-host interactions that modulate flavivirus host-specificity

STUDY_SECTION: MCV

STUDY_SECTION_NAME: Molecular and Cellular Biology of Virus Infection Study Section[MCV]


ED_INST_TYPE: SCHOOLS OF PUBLIC HEALTH

NIH_SPENDING_CATS: Biodefense and Related Countermeasures;Clinical Research;Emerging Infectious Diseases;Infectious Diseases;Prevention;Tickborne Diseases;Vector-Borne Diseases

ORG_CITY: SEATTLE

ORG_DEPT: PUBLIC HEALTH & PREV MEDICINE

ORG_NAME: UNIVERSITY OF WASHINGTON

ORG_STATE: WA

PHR: PROJECT NARRATIVE The proposed research is relevant to public health because it proposes a new methodological approach to studying and controlling zoonotic diseases, which represent a substantial threat to public health. A validated method for measuring and modeling human-livestock contact networks is expected to have positive impact as no empirically-derived human-animal network models exist, compelling zoonotic disease modelers to make oversimplifications which limit the validity of their findings. This project is relevant to NIAID’s mission to better understand and ultimately prevent infectious diseases because it is expected to open new horizons for targeting interventions and surveillance at the human-animal interface, optimizing cost effectiveness and facilitating more timely response before substantial human-to-human transmission has occurred.

PI_NAMEs: MEISNER, JULIANNE  (contact)

PROGRAM_OFFICER_NAME: PERDUE, SAMUEL S

PROJECT_TERMS: 2019-nCoV;Anaplasma marginale;Anaplasma phagocytophilum;Anaplasmosis;Animal Structures;Animals;Bayesian Analysis;Brucella;Brucellosis;Cessation of life;combat;Communicable Diseases;Communities;Complex;cost effectiveness;Coxiella;Data;design;Devices;diaries;Disease;disease model;disease transmission;Ego;emerging pathogen;Ensure;Environmental Health;Epidemic;epidemiological model;Epidemiology;Event;Foot Diseases;Foundations;Frequencies;Funding;generative models;Goals;Health;Hour;Household;Human;human model;improved;Individual;insight;interest;Interruption;Intervention;Left;Leptospira;Leptospirosis;Livestock;mathematical model;Measures;Methodology;Methods;Mission;Modeling;Molecular;Mongolia;Monkeypox;Morbidity - disease rate;Mouth Diseases;Names;National Institute of Allergy and Infectious Disease;network models;novel;Outcome;pathogen;Pathogenicity;Pathway Analysis;Pathway interactions;Poverty;prevent;Province;Public Health;Q Fever;Qualitative Research;Random Allocation;Reaction Time;Research;Research Personnel;Resources;Respiratory Tract Infections;Risk;risk stratification;Route;Sampling;Sexually Transmitted Diseases;statistics;Structure;surveillance strategy;Surveys;System;Testing;Time;transmission process;Zoonoses

PROJECT_TITLE: Disease transmission along complex human-animal networks: a novel method for improving zoonotic disease modeling

STUDY_SECTION: TVZ

STUDY_SECTION_NAME: Transmission of Vector-Borne and Zoonotic Diseases Study Section [TVZ]


ORG_CITY: SAINT LOUIS

ORG_NAME: WASHINGTON UNIVERSITY

PHR: Project Narrative Respiratory disease represents a major health care problem. Indeed, influenza and pneumonia, as well as chronic respiratory (lung) diseases, are among the top ten leading causes of death in the U.S. population. The purpose of our pulmonary research training program is to develop new leaders and innovators to drive research and development in the field of lung biology and disease and thereby solve this problem.

PI_NAMEs: BRODY, STEVEN ;HOLTZMAN, MICHAEL J (contact);LEE, JANET SOJUNG

PROGRAM_OFFICER_NAME: REYES, MADELYN

PROJECT_TERMS: Lung;Research

PROJECT_TITLE: Principles in Pulmonary Research

STUDY_SECTION: NITM

STUDY_SECTION_NAME: NHLBI Institutional Training Mechanism Study Section[NITM (JA)]


PHR: PROJECT NARRATIVE The goal of this SPORE is to develop and test new therapies for acute myeloid leukemia, acute lymphoid leukemia, and myelodysplastic syndrome. This SPORE also will identify and train new investigators in leukemia research.

PI_NAMEs: LINK, DANIEL C (contact)

PROGRAM_OFFICER_NAME: KUZMIN, IGOR A

PROJECT_TERMS: Acute Lymphocytic Leukemia;Acute Myelocytic Leukemia;Acute T Cell Leukemia;Allogenic;AML/MDS;Basic Science;Bioinformatics;Biometry;cancer genomics;Cancer Research Project;CAR T cell therapy;career;CD7 gene;Cells;chimeric antigen receptor T cells;Clinic;Clinical;Collaborations;Communities;Correlative Study;cytotoxicity;Data;Decitabine;Development;disabled;DNA;DNA biosynthesis;Dysmyelopoietic Syndromes;Education;Female;first-in-human;Genomics;Goals;Grant Review;Hematopoiesis;Hematopoietic Stem Cell Transplantation;high risk;Homologous Transplantation;Immunologics;Immunology;Infrastructure;inhibitor;innovation;Institution;Intention;Joints;leukemia;leukemia relapse;leukemia treatment;Malignant Neoplasms;Medicine;meetings;Memorial Sloan-Kettering Cancer Center;Memory;Mentors;Molecular;Multi-Institutional Clinical Trial;mutant;Mutate;Mutation;Myeloproliferative disease;Natural Killer Cell Immunotherapy;next generation;NK cell therapy;novel;novel marker;novel strategies;novel therapeutics;Oral;PARP inhibition;Patients;peer;phase 2 study;Phase I Clinical Trials;Poly(ADP-ribose) Polymerase Inhibitor;Postbaccalaureate;pre-clinical;preclinical study;Production;Program Reviews;programs;recruit;Refractory;Relapse;replication stress;Research;Research Personnel;Research Project Grants;Resolution;Resources;response;RNA Splicing;Specialized Program of Research Excellence;T-Lymphocyte;targeted treatment;Testing;Therapeutic Trials;TP53 gene;Training;Training Programs;Translating;translational cancer research;Translational Research;translational scientist;Universities;Washington

PROJECT_TITLE: Specialized Program of Research Excellence (SPORE) in Leukemia

STUDY_SECTION_NAME: Special Emphasis Panel[ZCA1 RPRB-N (M1)]


NIH_SPENDING_CATS: Cancer;Clinical Research;Clinical Trials and Supportive Activities;Hematology;Rare Diseases

PROJECT_TERMS: Address;Advocacy;Advocate;Animals;career;Clinical Research;Clinical Trials;Collaborations;Communication;Contracts;data sharing;design;Development;diversity and equity;Documentation;Education;Educational workshop;Electronic Publishing;experience;Faculty;Family;Funding;Goals;Grant;Guidelines;Human;Institution;Journals;leukemia;Manuscripts;Medicine;meetings;member;Mentors;Minority;Minority Participation;Monitor;Newsletter;Paper;Patients;peer;Peer Review;Physicians;Pilot Projects;Postbaccalaureate;Preparation;Program Reviews;programs;Progress Reports;Protocols documentation;Publications;Publishing;PubMed;recruit;Research;Research Personnel;Review Committee;Specialized Program of Research Excellence;Travel;United States National Institutes of Health;Universities;Washington

PROJECT_TITLE: Administrative Core


NIH_SPENDING_CATS: Biotechnology;Cancer;Childhood Leukemia;Clinical Research;Clinical Trials and Supportive Activities;Gene Therapy;Gene Therapy Clinical Trials;Genetics;Hematology;Immunotherapy;Orphan Drug;Pediatric;Pediatric Cancer;Rare Diseases

PHR: Project 1 Narrative T cell malignancies represent a class of hematologic cancers with high rates of relapse and mortality in both children and adults for which there are currently no effective or targeted therapies. We have developed a fratricide-resistant “off-the-shelf” chimeric antigen receptor T cell that targets CD7+ T cell malignancies (UCART7) and, through CRISPR/Cas9 gene editing, lacks both CD7 and T cell receptor alpha chain expression thereby preventing graft-versus-host disease when infused into allogeneic recipients. We propose to test UCART7 in patients with relapse or refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and use preclinical mouse models to determine if UCART therapy can be improved using cytokines (IL-7 and IL-15), dual phosphoinositide 3-kinase delta/gamma inhibitors (duvelisib) and/or dual-targeted UCART.

PI_NAMEs: DIPERSIO, JOHN F. (contact)

PROJECT_TERMS: Acute T Cell Leukemia;acute T-cell lymphoblastic leukemia cell;Address;Adult;Allogenic;Antibodies;Antigen Targeting;Antigens;Autologous;Binding;Biological;cancer cell;cancer immunotherapy;CAR T cell therapy;CD7 gene;CD8-Positive T-Lymphocytes;Cell Line;Cells;Cellular Indexing of Transcriptomes and Epitopes by Sequencing;Child;chimeric antigen receptor;chimeric antigen receptor T cells;Clinical;clinical development;Complex;Correlative Study;CRISPR/Cas technology;cytokine;cytokine release syndrome;cytotoxicity;Development;Down-Regulation;effective therapy;effector T cell;efficacy study;engineered T cells;Flow Cytometry;Gene Modified;Genes;Goals;graft vs host disease;Half-Life;Harvest;Hematologic Neoplasms;Hour;Human;Hybrids;IgG1;IL7 gene;Immune;Immunocompetent;improved;In Vitro;in vivo;inhibitor;Interleukin 2 Receptor Gamma;Interleukin-15;interleukin-15 receptor;kinase inhibitor;leukemia;Life;Lymphoma;Malignant - descriptor;Malignant Neoplasms;man;Medical;mortality;mouse model;Mus;mutant;Mutation;Natural Killer Cells;Outcome;Pathway interactions;Patients;Peripheral;Phase;phase I trial;Phenotype;Phosphatidylinositols;Phosphotransferases;pre-clinical;preclinical study;prevent;Proliferating;Prophylactic treatment;receptor;Recombinants;Recurrent disease;Refractory;Relapse;Resistance;risk mitigation;Safety;safety study;Serum;Signal Transduction;Specialized Program of Research Excellence;T cell therapy;T-Cell Receptor;T-Lymphocyte;targeted treatment;Testing;Toxic effect;tumor;Tumor Escape;Work

PROJECT_TITLE: Project 1: Chimeric antigen receptor T-cell therapy for T cell malignancies


NIH_SPENDING_CATS: Biotechnology;Cancer;Childhood Leukemia;Clinical Research;Clinical Trials and Supportive Activities;Gene Therapy;Gene Therapy Clinical Trials;Genetics;Hematology;Immunotherapy;Orphan Drug;Pediatric;Pediatric Cancer;Rare Diseases;Regenerative Medicine;Stem Cell Research;Stem Cell Research - Nonembryonic - Human;Transplantation

PHR: Our research will test a new cellular immunotherapy, called memory-like natural killer cells, in a clinical trial for patients with acute myeloid leukemia who have relapsed after allogeneic hematopoietic cell (bone marrow) transplantation. Additional goals of this research are to identify correlates of leukemia response or resistance to this new treatment, impact on other components of the immune system, and to test new approaches to optimize the response and recognition of AML by memory-like NK cells. We also expect that this research will lead to new combination immunotherapy treatments for patients with leukemia in the future.

PI_NAMEs: FEHNIGER, TODD A (contact)

PROJECT_TERMS: Acute Myelocytic Leukemia;acute myeloid leukemia cell;Adult Acute Myeloblastic Leukemia;Allogenic;Antigen Presentation;Automobile Driving;Biological Assay;Bone Marrow;Cell Physiology;Cell Therapy;Cells;Cellular immunotherapy;Cellular Indexing of Transcriptomes and Epitopes by Sequencing;chemotherapy;Childhood Acute Myeloid Leukemia;chimeric antigen receptor;chimeric antigen receptor natural killer cells;Clinic;Clinical;Clinical Trials;cohort;Cohort Studies;Combination immunotherapy;Cyclophosphamide;cytokine;Detection;Disease remission;disorder control;Donor Lymphocyte Infusion;Dose;Engineering;exhaustion;Flow Cytometry;flu;fludarabine;Future;Goals;graft failure;graft vs host disease;graft vs leukemia effect;Hematopoietic;Hematopoietic Stem Cell Transplantation;high risk;Homologous Transplantation;Human;IL18 gene;IL3RA gene;Immune;immune effector cell-associated neurotoxicity syndrome;Immune system;Immunology;immunoregulation;Immunotherapy;immunotherapy clinical trials;improved;In Vitro;in vivo;in vivo evaluation;innovation;Interferon Type II;Interleukin-12;Interleukin-15;Interleukin-2;leukemia;leukemia relapse;Longevity;Mediating;Memory;Natural Killer Cell Immunotherapy;Natural Killer Cells;NK cell therapy;novel;novel strategies;Outcome;Patients;Phase;phase 2 study;Phase I Clinical Trials;phase II trial;Positioning Attribute;pre-clinical;Prognosis;receptor;Refractory;Relapse;Research;Research Design;Resistance;response;Safety;Sampling;Source;Specialized Program of Research Excellence;standard care;standard of care;T cell response;T-Lymphocyte;Testing;Translating;Transplantation;Work;Xenograft procedure

PROJECT_TITLE: Project 2: Memory-like NK cell therapy for AML relapsed after allogeneic transplant


NIH_SPENDING_CATS: Biotechnology;Cancer;Childhood Leukemia;Clinical Research;Clinical Trials and Supportive Activities;Genetics;Hematology;Orphan Drug;Pediatric;Pediatric Cancer;Rare Diseases

PHR: We and others discovered that RNA splicing factors are mutated in the blood cells of many patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), leading to the formation of DNA:RNA hybrids in cells (i.e., R loops) and activation of ATR and PARP1 DNA damage response pathways. Inhibition of ATR or PARP cause splicing factor mutant cells to die and the combination is synergistic. This project will optimize the combination of ATR and PARP1 inhibition in preclinical models, providing the rationale for an investigator-initiated clinical trial.

PI_NAMEs: WALTER, MATTHEW J (contact)

PROJECT_TERMS: Acute Myelocytic Leukemia;acute myeloid leukemia cell;Adult;AML/MDS;Apoptosis;Automobile Driving;Biological Markers;Bioluminescence;Blood;Blood Cells;Body Weight;Cell Death;Cell Line;Cells;CHEK1 gene;Chimerism;Chromatin;Clinic;Clinical;Clinical Trials;combinatorial;Combined Modality Therapy;congenic;Cytoprotection;Data;DNA;DNA Damage;DNA damage checkpoint;DNMT3a;Dysmyelopoietic Syndromes;ETV6 gene;Flow Cytometry;Funding;Gene Expression;Gene Mutation;Generations;Genes;Genetic Transcription;Genomic Instability;Goals;Hematologic Neoplasms;Hematology;Human;Human Cell Line;Hybrids;In Vitro;in vitro Model;in vivo;inhibitor;investigator-initiated trial;Label;leukemia;Leukemic Cell;loss of function mutation;Luciferases;Malignant Neoplasms;Measurement;Measures;Mediating;Metabolism;MLLT3 gene;Modeling;Mus;mutant;Mutant Strains Mice;Mutate;Mutation;Myeloproliferative disease;novel;novel drug combination;novel therapeutics;Oral;PARP inhibition;Pathway interactions;patient population;Patients;Phase II Clinical Trials;phase II trial;Phenocopy;Phosphotransferases;Pre-Clinical Model;Predisposition;Recurrence;Refractory;Regulation;Relapse;replication stress;Reporting;Research Personnel;Resistance;resistance mechanism;Resolution;response;response biomarker;RNA;RNA Splicing;RUNX1 gene;Sampling;Signal Transduction;Single-Stranded DNA;Solid Neoplasm;Specialized Program of Research Excellence;Spliceosomes;SRSF2 gene;Structure;System;targeted treatment;Testing;tool;Toxic effect;transcriptome sequencing;Translating;Transplantation;Tumor Volume;Xenograft procedure

PROJECT_TITLE: Project 3: Targeted therapy for splicing factor mutant myeloid malignancies


NIH_SPENDING_CATS: Biotechnology;Cancer;Cancer Genomics;Childhood Leukemia;Clinical Research;Clinical Trials and Supportive Activities;Genetics;Hematology;Human Genome;Orphan Drug;Pediatric;Pediatric Cancer;Rare Diseases

PHR: PROJECT NARRATIVE The prognosis for patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) carrying TP53 mutations is dismal and there is an urgent need for better therapies. We have generated preclinical data suggesting that TP53-mutated AML/MDS is selectively vulnerable to the combination of decitabine and an ATR inhibitor. Here, we will conduct and phase I clinical trial of this novel combination therapy in patients withTP53- mutated AML/MDS.

PROJECT_TERMS: Acute Myelocytic Leukemia;acute myeloid leukemia cell;Address;adduct;Allogenic;AML/MDS;Anaphase;Apoptosis;Base Excision Repairs;bisulfite sequencing;CDKN1A gene;Cell Cycle;Cell Cycle Arrest;Cell Line;CHEK1 gene;Clinical;Clinical Trials Network;Combined Modality Therapy;Comet Assay;Correlative Study;CRISPR/Cas technology;Cytarabine;cytotoxicity;Data;Daunorubicin;Decitabine;design;DNA;DNA biosynthesis;DNA Damage;DNA fiber assay;DNA Methylation;DNA replication fork;DNA Replication Induction;Dose;Dropout;Dysmyelopoietic Syndromes;effective therapy;Flow Cytometry;Gamma-H2AX;Gene Frequency;Generations;Genes;genetic approach;Genetic Determinism;Genetic Transcription;genetic variant;genome sequencing;genome-wide;Hematopoietic Stem Cell Transplantation;high risk;human model;inhibitor;insight;Investigational Therapies;leukemia;M cell;Measures;Mitotic;Molecular;mouse model;mutant;Mutate;Mutation;Neoadjuvant Therapy;new therapeutic target;novel;Nuclear;Nucleosides;open label;Oral;p53-binding protein 1;patient prognosis;Patients;Pharmacodynamics;pharmacologic;Phase;phase 1 study;Phase I Clinical Trials;Phenotype;Play;pre-clinical;primary endpoint;Prognostic Factor;Randomized;Recommendation;relapse patients;replication stress;Resistance;Resolution;response;Role;Safety;Sampling;single molecule;Specialized Program of Research Excellence;Speed;Stress;success;synergism;Testing;Therapeutic;Therapeutic Intervention;Therapy-Related Acute Myeloid Leukemia and Myelodysplastic Syndrome;TP53 gene;TP53-mutant acute myeloid leukemia;Ultrafine;Western Blotting;whole genome;Xenograft procedure

PROJECT_TITLE: Project 4: Targeting ATR in TP53-mutated MDS/AML


NIH_SPENDING_CATS: Cancer;Cancer Genomics;Clinical Research;Clinical Trials and Supportive Activities;Genetics;Hematology;Human Genome;Rare Diseases

PI_NAMEs: JACOBY, MEAGAN  (contact)

PROJECT_TERMS: Accreditation;anti-cancer research;biobank;Biological Specimen Banks;Blood;Bone Marrow;Cancer Center;career;Cataloging;Catalogs;Cells;Characteristics;Clinical;Clinical Data;clinical database;clinically relevant;Communities;Consent;data sharing;Development;Disease;DNA Sequence Alteration;Enrollment;epidemiologic data;Equipment and supply inventories;Equity;Exclusion;experience;Future;Genomics;Goals;Health Insurance Portability and Accountability Act;Hematologic Neoplasms;informatics tool;Infrastructure;Institution;Institutional Review Boards;Investigation;leukemia;Link;Mission;Multiple Myeloma;Newly Diagnosed;Nucleic Acids;Outcome;Pathogenesis;Patients;Preparation;preservation;Process;Prognostic Factor;Program Research Project Grants;programs;prospective;Protocols documentation;Qualifying;Research;Research Personnel;Research Project Grants;Resources;Serum;Skin;Specialized Program of Research Excellence;Specimen;Time;Tissue Procurements;Tissues;translational cancer research;Universities;Washington

PROJECT_TITLE: Core A: Biospecimen Processing


NIH_SPENDING_CATS: Bioengineering;Cancer;Cancer Genomics;Clinical Research;Clinical Trials and Supportive Activities;Data Science;Genetics;Hematology;Human Genome;Networking and Information Technology R&D (NITRD);Rare Diseases

PI_NAMEs: COLDITZ, GRAHAM A. (contact)

PROJECT_TERMS: algorithm development;Bioinformatics;bioinformatics pipeline;bioinformatics tool;Biometry;Biostatistics Core;Cancer Center;career;Cells;Clinical Research;Cloud Computing;Collaborations;Consultations;Data Analyses;data integration;data management;Data Set;data sharing;data visualization;database of Genotypes and Phenotypes;Databases;design;Development;Ensure;epigenomics;experience;genomic data;Genomic Data Commons;Genomics;High Performance Computing;Informatics;leukemia;Malignant Neoplasms;medical schools;meetings;member;Minority;Monitor;multidimensional data;Multiomic Data;Program Research Project Grants;programs;Quality Control;Reproducibility;Research;research and development;Research Design;Research Personnel;RNA analysis;Specialized Program of Research Excellence;Statistical Data Interpretation;Statistical Methods;Statistical Study;System;Training;transcriptomics;Universities;Visualization;Washington;Work

PROJECT_TITLE: Core B: Biostatistics and Bioinformatics


NIH_SPENDING_CATS: Cancer;Clinical Research;Clinical Trials and Supportive Activities;Health Disparities Research;Health Disparities and Racial or Ethnic Minority Health Research;Hematology;Rare Diseases

PI_NAMEs: SCHUETTPELZ, LAURA G. (contact)

PROJECT_TERMS: Award;Basic Science;Cancer Center;Cancer Control Research;cancer health disparity;cancer prevention;career;Clinical;Clinical Research;Clinical Trials;Collaborations;community based research;community engagement;Community Outreach;Development;disabled;Disparity;epidemiology study;experience;Faculty;Fostering;Funding;Future;Goals;Group Meetings;Health Disparities Research;Institution;interest;Laboratories;Leadership;leukemia;Medicine;meetings;Mentors;outreach;Patient Recruitments;Peer Review;Program Research Project Grants;programs;recruit;Research;Research Design;Research Personnel;Research Project Grants;Resources;Specialized Program of Research Excellence;Translational Research;Underrepresented Minority;United States National Institutes of Health;Wages;Woman;Work;Writing

PROJECT_TITLE: Developmental Research Program


PI_NAMEs: LEY, TIMOTHY J. (contact)

PROJECT_TERMS: Applications Grants;Award;Basic Science;Biometry;career;career development;Clinical;Clinical Investigator;Clinical Trials Design;Collaborations;Development Plans;Diagnosis;disabled;Discipline;Early Diagnosis;Education;Educational Status;Ethics;Etiology;Faculty;Feedback;Financial Support;Fostering;Funding;Goals;graduate school;Grant;Grant Review;Individual;Institution;Laboratories;Leadership;leukemia;medical schools;Medicine;Mentors;multidisciplinary;Patient Care;patient oriented;peer;Population Sciences;Postbaccalaureate;Prevention;Professional Competence;Program Reviews;programs;recruit;Research;research and development;Research Personnel;Research Training;Scientist;skill acquisition;Specialized Program of Research Excellence;Students;Training;Translational Research;Universities;Visit;Wages;Washington;Woman;Work

PROJECT_TITLE: Career Enhancement Program


ORG_CITY: STANFORD

ORG_DEPT: RADIATION-DIAGNOSTIC/ONCOLOGY

ORG_NAME: STANFORD UNIVERSITY

ORG_STATE: CA

PHR: PROJECT NARRATIVE. Ferroptosis is a form of regulated cell death that is characterized by the accumulation of lipid peroxides, leading to oxidative damage, plasma membrane disruption, and cell death. Ferroptosis is partly mediated by the amino acid transporter, system xc-, owing to the critical role of system xc- in regulating cellular antioxidant defenses and redox balance. This proposal will test the hypothesis that [18F]hGTS13, a system xc- specific radiotracer, can inform on the sensitivity of different cancers to ferroptosis and monitor pharmacological induction of ferroptosis, additionally, we will translate [18F]hGTS13 for first-in-human investigation.

PI_NAMEs: RAO, JIANGHONG  (contact)

PROGRAM_OFFICER_NAME: DARDZINSKI, BERNARD JOSEPH

PROJECT_TERMS: Amino Acid Transporter;Anabolism;anti-cancer research;Antioxidants;antiporter;Apoptosis;Attenuated;Biodistribution;Biology;Cancer Biology;cancer cell;Cancer cell line;Cancer Detection;cancer imaging;Cancer Model;cancer therapy;carcinogenesis;Caspase;Cell Culture Techniques;Cell Death;Cell membrane;cell type;Cells;Cessation of life;Clinical;clinical investigation;Clinical Research;clinical translation;clinically relevant;Communities;comparative;Cysteine;Cystine;Dependence;Development;Discipline of Nuclear Medicine;Dose;dosimetry;Drug Kinetics;drug mechanism;Drug Monitoring;Drug resistance;Equilibrium;Exhibits;Female;first-in-human;Foundations;Generations;Glutamates;Glutathione;glutathione peroxidase;Goals;healthy volunteer;Homeostasis;Homo;Human;Human Volunteers;imaging biomarker;imaging modality;imaging system;Immune;improved;In Vitro;in vivo;Inflammation;inhibitor;interest;Investigation;Investigational Drugs;Investigational New Drug Application;Iron;iron metabolism;knock-down;Knowledge;Lipid Peroxides;male;Malignant neoplasm of lung;Malignant Neoplasms;Mediating;Membrane Lipids;Membrane Transport Proteins;Modeling;molecular imaging;Monitor;Morphology;non-invasive imaging;novel;Oxidation-Reduction;oxidative damage;Oxidative Stress;Pathway interactions;Patient Selection;PET/CT scan;Pharmaceutical Preparations;pharmacologic;Pharmacological Treatment;Play;Positioning Attribute;Positron-Emission Tomography;Pre-Clinical Model;predicting response;Prediction of Response to Therapy;Predisposition;Process;Production;Quality Control;Radiochemistry;Radiometry;Radiopharmaceuticals;radiotracer;Rattus;Regulation;Reporting;Research Personnel;Resistance;Role;Safety;Small Interfering RNA;Specificity;System;Testing;Therapeutic;therapeutic target;Toxic effect;Tracer;Translating;Translations;treatment effect;tumor;Tumor Volume;Universities;uptake;Visualization;Work;X-Ray Computed Tomography;Xenograft procedure

PROJECT_TITLE: Novel applications and translation of [18F]hGTS13, a system xc- specific radiopharmaceutical

STUDY_SECTION: IPCA

STUDY_SECTION_NAME: Imaging Probes and Contrast Agents Study Section[IPCA]


NIH_SPENDING_CATS: Aging;Genetics

ORG_NAME: INSTITUTE FOR SYSTEMS BIOLOGY

PHR: Narrative This project aims to develop a new tool to assess the overall health of a mouse and predict early in a mouse’s life when it will die. This assessment will be an important tool for the aging research field to increase the efficiency of studies looking at interventions to delay aging, and to help us understand the underlying mechanisms of the aging process.

PI_NAMEs: KANE, ALICE E (contact)

PROGRAM_OFFICER_NAME: FU, YI-PING

PROJECT_TERMS: Age;Age related pathologies;Aging;aging mechanism;aging process;Blood;Blood specimen;C57BL/6 Mouse;Cessation of life;Consumption;Data;Development;DNA Methylation;epigenetic clock;Epigenetic Process;Female;frailty;Health;health data;histone modification;Human;indexing;Intervention;Investigation;Life;life span;Longevity;machine learning model;male;Measures;Modeling;Molecular;mortality;mouse model;Mus;old mice;Outcome Measure;Physiological;Postdoctoral Fellow;Research;sex;stool sample;Testing;Time;tool;Work

PROJECT_TITLE: Development of a Predictive Frailty Clock & Longitudinal Investigation of its Epigenetic Determinants


NIH_SPENDING_CATS: Acquired Cognitive Impairment;Aging;Alzheimer's Disease;Alzheimer's Disease Related Dementias (ADRD);Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD);Bioengineering;Brain Disorders;Dementia;Genetics;Lewy Body Dementia;Neurodegenerative;Neurosciences;Parkinson's Disease

ORG_CITY: SAN FRANCISCO

ORG_NAME: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO

PHR: Project Narrative Alzheimer's disease and Alzheimer's disease related dementias (AD/ADRD) are heterogeneous diseases whose causes and progression depend on the interactions of many factors, including trans-neuronal transmission of “prion-like” proteins, such as tau and α-synuclein, and regional gene expression. Here we use powerful mathematical modeling and a combination of in vitro and in vivo approaches to jointly evaluate how these two mechanisms interact as well as identify key genes that serve as important mediators of the transmission process.

PI_NAMEs: PENG, CHAO ;RAJ, ASHISH  (contact)

PROGRAM_OFFICER_NAME: DIBATTISTA, AMANDA

PROJECT_TERMS: alpha synuclein;Alzheimer's Disease;Alzheimer's disease model;Alzheimer's disease related dementia;Amyloid;Amyloid beta-Protein;Amyloidosis;Animal Model;Atlases;Back;Beds;beta amyloid pathology;Brain;Brain region;Candidate Disease Gene;candidate identification;Clinical;computational platform;computer framework;conformer;connectome;Data;Data Set;Deposition;Discipline;Disease;disease heterogeneity;disease model;Disease Progression;drug development;experimental study;Functional disorder;Future;Gene Expression;Gene Expression Process;gene regulatory network;Generations;Genes;Genetic;Heterogeneity;high throughput screening;human disease;improved;in silico;In Vitro;in vitro Model;in vivo;in vivo Model;Injections;insight;Joints;Lewy Body Dementia;mathematical model;Mediating;Mediation;Mediator;Methods;Modeling;Molecular;Molecular Conformation;mouse model;Mus;network models;Neurodegenerative Disorders;Neurons;neurotransmission;new therapeutic target;novel;Pathologic;Pathology;Patients;Pattern;Performance;Phase;predictive modeling;prion-like;Process;Proteins;Proteomics;Proxy;regional difference;screening;success;synucleinopathy;System;Systems Biology;tau conformation;tau Proteins;Tauopathies;Testing;Time;transcriptomics;Translating;transmission process;Validation;Wild Type Mouse;Work

PROJECT_TITLE: Exploring the differential spreading of distinct pathological conformers of AD/LBD-related proteins by combining mathematical modeling and functional study

STUDY_SECTION_NAME: Special Emphasis Panel[ZAG1 ZIJ-2 (M2)]


ORG_DEPT: NEUROSURGERY

PHR: OVERALL: PROJECT NARRATIVE The overall goal of this renewal P01 proposal is to identify imaging and genomic signatures of brain tumor heterogeneity and evolution to optimize patient management of the two most common primary brain tumors in adults: glioblastoma and meningioma. This will be achieved by integrating multi-parametric imaging strategies assessing spatial and temporal changes in individual patients during the course of their disease along with genomic properties of the tumor. We will ascertain non-invasive imaging markers that reflect the underlying biological mechanisms driving glioblastoma evolution and mengingioma molecular differentiation to improve patient care through informing new therapeutic targets and ways to monitor early response.

PI_NAMEs: CHANG, SUSAN M (contact);LUPO, JANINE MARIE;VIGNERON, DANIEL B

PROGRAM_OFFICER_NAME: WANG, YISONG

PROJECT_TERMS: Acceleration;Achievement;Address;Adult;Alanine;alpha ketoglutarate;Automobile Driving;Biological;Biological Markers;Brain Neoplasms;cancer imaging;Categories;Cell Line;Characteristics;Classification;Clinical;clinical application;Clinical Services;clinical translation;Development;Disease;DNA Methylation;Early treatment;Evaluation;Evolution;experience;Fostering;FOXM1 gene;Gene Expression;genomic data;genomic signature;Genomics;Glioblastoma;Glioma;Glutamates;Goals;Grant;Grouping;Heterogeneity;Human;Image;imaging biomarker;imaging modality;imaging probe;imaging scientist;Imaging Techniques;improved;individual patient;Infrastructure;innovation;insight;Intracranial Neoplasms;Knowledge;Label;Leadership;Lesion;Magnetic Resonance Imaging;meningioma;Metabolic;metabolic imaging;Modeling;Molecular;molecular imaging;molecular subtypes;Monitor;multidisciplinary;multiparametric imaging;Mutate;Mutation;Neurofibromin 2;new therapeutic target;Newly Diagnosed;non-invasive imaging;novel;novel therapeutic intervention;novel therapeutics;Operative Surgical Procedures;Organoids;Outcome;Patient Care;Patients;pre-clinical;preclinical evaluation;Primary Brain Neoplasms;prognostic;promoter;Property;Pyruvate;Radiation;Recurrence;Research;Research Personnel;Resistance;Resources;response;Role;Sampling;standard care;success;System;targeted treatment;Techniques;Technology;Therapeutic;therapeutic target;Three-Dimensional Imaging;Time;Tissue Sample;Translating;translational cancer research;Translations;treatment response;tumor;tumor diagnosis;tumor heterogeneity;tumor metabolism;Tumor Pathology;Validation;Work

PROJECT_TITLE: Imaging and Genomic Signatures of Brain Tumor Heterogeneity and Evolution to Optimize Patient Management

STUDY_SECTION_NAME: Special Emphasis Panel[ZCA1 SRB-F (M1)]


NIH_SPENDING_CATS: Biomedical Imaging;Brain Cancer;Brain Disorders;Cancer;Clinical Research;Health Services;Neurosciences;Patient Safety;Precision Medicine;Rare Diseases

PHR: ADMINISTRATIVE AND CLINICAL SERVICES CORE: PROJECT NARRATIVE The proposed P01 consists of four highly integrated projects and shared resources (Biospecimen and Biomarker Core and Imaging Tumor Heterogeneity & Metabolism Core) focused on identifying imaging and genomic signatures of brain tumor heterogeneity and evolution to optimize patient management of the two most common primary brain tumors in adults: glioblastoma and meningioma. This Core will provide administrative and fiscal oversight for all four projects and clinical services for the three projects that will be performing patient studies.

PI_NAMEs: CHANG, SUSAN M (contact)

PROJECT_TERMS: Adult;Adverse event;Biological Markers;Brain Neoplasms;Cancer Center;cancer imaging;Clinical;Clinical Data;Clinical Management;Clinical Protocols;Clinical Research;Clinical Services;Collaborations;Communication;Comprehensive Cancer Center;Consent;Data;Databases;design;Effectiveness;Ensure;Evaluation;Evolution;experience;Family;follow-up;Funding;genomic signature;Glioblastoma;Goals;Grant;Heterogeneity;Human Resources;Image;imaging study;Individual;Informed Consent;Infrastructure;Institutional Review Boards;Laboratories;Leadership;Link;Manuscripts;meetings;member;meningioma;metabolic imaging;Monitor;neuro-oncology;Neurosurgeon;novel;Nursing Research;operation;parent grant;participant enrollment;Patient imaging;Patient Rights;Patients;Pharmaceutical Preparations;Preparation;Primary Brain Neoplasms;Procedures;programs;Progress Reports;Protocols documentation;radiologist;Reporting;Research;Research Assistant;Research Personnel;Research Project Grants;research study;Research Support;Resource Sharing;Resources;Safety;Scientist;Specific qualifier value;success;Tissues;Toxic effect;tumor heterogeneity;tumor metabolism;United States National Institutes of Health

PROJECT_TITLE: Core A: Administrative and Clinical Services Core (ACS)


NIH_SPENDING_CATS: Biotechnology;Brain Cancer;Brain Disorders;Cancer;Cancer Genomics;Genetics;Human Genome;Neurosciences;Orphan Drug;Precision Medicine;Rare Diseases

PHR: PROJECT 1: PROJECT NARRATIVE Intratumor heterogeneity underlies treatment failure in glioblastoma and is poorly understood because only a tiny fraction of the tumor is available usually. Our multi-disciplinary team will use imaging-based whole tumor sampling with genomics to delineate the roots of glioblastoma for each patient, fostering the development of better models and new therapies. The project will enable new therapeutic strategies aimed at an untapped source of therapeutic targets that could avoid the major source of failures, broadly increasing the probability of clinical impact.

PI_NAMEs: COSTELLO, JOSEPH F (contact)

PROJECT_TERMS: 3-Dimensional;Back;Biological Assay;Brain Neoplasms;Cell Lineage;Cell model;cell transformation;Cells;Cellular Assay;Chromatin;Clinical;Clonal Expansion;Clone Cells;cohort;Complex;Computers;Data;data exploration;data resource;design;Development;Diagnosis;DNA Sequence Alteration;Epigenetic Process;epigenome;epigenomics;Evolution;experimental study;Failure;Fostering;Foundations;Fresh Tissue;fusion gene;Future;Gene Expression;Gene Fusion;Genes;genome analysis;genomic data;genomic signature;Genomics;Glioblastoma;Goals;Hi-C;Human;Image;immunogenic;immunogenicity;improved;individual patient;Internet;Investigation;knock-down;Location;Magnetic Resonance Imaging;Malignant Neoplasms;Maps;Methods;Modeling;multidisciplinary;multiparametric imaging;Mutation;neoantigens;neoplastic cell;Newly Diagnosed;novel therapeutic intervention;novel therapeutics;Oncogenes;Patients;Peptides;personalized immunotherapy;personalized medicine;Precision therapeutics;Probability;programs;Recurrence;Sampling;Source;Testing;The Cancer Genome Atlas;Therapeutic;therapeutic development;therapeutic target;Time;time use;Tissue Sample;transcriptome sequencing;Treatment Failure;tumor;tumor diagnosis;Tumor Expansion;tumor heterogeneity;Tumor Suppressor Genes;Tumor Tissue;Variant;Visualization;web app

PROJECT_TITLE: Project 1: Spatial imaging of whole tumor genomics to understand glioblastoma formation and evolution


PHR: PROJECT 2: PROJECT NARRATIVE  The goal of this project is to understand mechanisms driving meningioma evolution and heterogeneity to (1) identify drivers underlying meningioma biomarker performance to optimize risk stratification, (2) define magnetic resonance imaging features of meningioma biomarkers to establish a foundation for non-invasive risk stratification, and (3) inform future therapies to improve the care of patients with meningiomas. Meningiomas are the most common primary intracranial tumors, but limited understanding of meningioma biology and the misconception that meningiomas are benign has encumbered medical and scientific advances for patients with meningiomas. To address these limitations, we will use prospective regionally distinct meningioma samples (Aim 1), retrospective patient-matched meningioma samples over time (Aim 2), and an organoid model of meningioma tumorigenesis integrated with a novel functional genomic technique that links genetic and therapeutic perturbations to genomic phenotypes in single cells (Aim 3) to define mechanisms driving meningioma evolution and heterogeneity.

PI_NAMEs: RALEIGH, DAVID R (contact)

PROJECT_TERMS: 3-Dimensional;Address;Automobile Driving;Benign Meningiomas;biobank;Bioinformatics;Biological;Biological Markers;Biology;biomarker performance;Brain Neoplasms;Cell Cycle;Cell Cycle Inhibition;Cell Line;Cells;Classification;Clinical Trials Cooperative Group;Collaborations;Copy Number Polymorphism;CRISPR interference;Data;Dependence;Development;DNA Methylation;Evolution;exome sequencing;Foundations;functional genomics;Future;Gene Expression Profiling;Genetic;Genetic Markers;genome-wide;genomic data;genomic signature;Genomics;Goals;Growth;Guidelines;Heterogeneity;Histologic;Histology;Human;Image;image guided;improved;Individual;inhibitor;inhibitor therapy;Institution;Intervention;Intracranial Neoplasms;Ionizing radiation;Letters;Libraries;Link;Magnetic Resonance Imaging;Medical;meningioma;Modeling;Molecular Profiling;Morbidity - disease rate;mortality;Neurologic;novel;novel therapeutics;Nuclear;Operative Surgical Procedures;Organoids;Outcome;Patient Care;Patients;Phenotype;Postoperative Period;prospective;Radiation therapy;Recurrence;Resistance;response;risk stratification;RNA;Sampling;Scientific Advances and Accomplishments;single-cell RNA sequencing;System;Techniques;Testing;Therapeutic;Time;transcription factor;transcriptomics;treatment response;tumor;tumor heterogeneity;tumorigenesis;Variant;Visualization;World Health Organization;XCL1 gene

PROJECT_TITLE: Project 2: Biological mechanisms and therapeutic vulnerabilities underlying meningioma evolution and heterogeneity